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ABSTRACT 
 HIV, hepatitis B and C virus (HBV, HCV) are three of the most common 
blood-borne infections and they continue to be a major public health problem in the 
United States (US) and globally. It is not well understood if maternal infection with either 
HBV or HCV has an adverse impact on pregnancy outcomes as findings from previous 
studies have provided some mixed results. The overall go l of this study was to assess the 
risk of preterm birth, low birth weight (LBW), small for gestational age (SGA) and 
admission into neonatal intensive care unit (NICU) for babies born to HBV- and HCV-
infected women. To this end, our objectives were to 1) describe the epidemiology of 
HBV and HCV and their co-infection with HIV in South Carolina (SC), 2) assess the 
spatial distribution of HCV infection in SC, and 3) estimate the risk of preterm birth, 
LBW, SGA, NICU admission in babies born to hepatitis- nfected mothers. Linked data 
from multiple sources for years 2004 to 2011 was utilized and descriptive statistics, 
Bayesian spatial and logistic regression analyses were conducted to evaluate the 
objectives of the study. Results revealed substantial variation in the epidemiology of 
these infections among females in SC to include an merging epidemic of HCV 
infections among young white females. The spatial an ysis identified Charleston, 
Darlington, Florence, Georgetown, Greenville, Horry, Oconee, McCormick and Richland 
counties as high-risk counties for HCV infection. Lastly, results from the logistic 
regression analysis supported the fact that low birth weight is independently associated 
with HCV infection during pregnancy, specifically, newly diagnosed mothers.  Our 
vii  
findings are useful for providers to advise infected expectant mothers on the potential risk 
to their baby. Local and state public health officials can also use these data for taking 
further public health action and make informed decisions on how to allocate limited 
resources to help prevent and reduce the spread on HCV and HBV infections within the 
state.  
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CHAPTER 1 
BACKGROUND AND OBJECTIVES 
1.1 Background 
Human Immunodeficiency Virus (HIV), hepatitis B and C virus (HBV, HCV) are three 
of the most common blood-borne infections and are a major public health problem in the 
United States (US) and globally.  Collectively, they cause significant morbidity and 
mortality from chronic liver diseases, hepatocellular carcinoma (HCC) and opportunistic 
infections among infected individuals 1-5.  According to the World Health Organization 
(WHO), approximately 2 billion people worldwide are infected with HBV and more than 
240 million of these people live with chronic HBV infection 6.  Likewise, HCV is 
widespread; the disease kills 350,000 people per year (1% of all deaths worldwide) and 
there are an estimated150 million people that are ch onically infected 7, 8. 
1.1.1 Epidemiology of HBV, HCV and HIV Co-infection 
Hepatitis simply refers to inflammation of the liver. HBV and HCV infection 
primarily affects the liver and is usually symptomless for decades. Acute infection with 
HBV or HCV is short-term (6 months) whereas chronic i fection is a lifelong illness that 
occurs if the infection remains in the body beyond six months. If untreated, the virus 
causes considerable damage to the liver that can lead to cirrhosis, liver cancer and death. 
Patterns of HBV infection vary worldwide and its geo raphic distribution to the 
prevalence of certain risk factors for HBV infection. In regions of high endemicity such 
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as Asia and sub-Saharan Africa where HBV prevalence is greater than 8% 9, major risk 
factors for HBV infection include perinatal transmission, blood transfusions and sexual 
contact. On the contrary, in regions of low endemicity, intravenous drug use is considered 
to be leading risk factor for HBV infection.  Global variation in HCV prevalence is also 
evident, as the disease tends to be higher in developing countries, especially those in 
North Africa. For instance, with nearly 15% of population infected, Egypt has one of 
worst affected populations in the world 8, 10.  
In the US, a region where HBV and HCV infections are considered to be low in 
prevalence, the Centers for Disease Control and Prevention (CDC) reported 10, 515 new 
sentinel cases of chronic HBV and 25,974 new sentinl cases of chronic HCV in 2010. It 
is believed that between 1.25 million and 2 million ndividuals are infected with HBV in 
the US, more than 50% of which are of Asian ethnicity 11, 12. When we consider 
incarcerated, homeless and active military persons otherwise not found in population-
based surveys, the numbers for those affected by HBV and HCV is significantly higher. 
One study conservatively cited 5.2 million as the tru  number of persons living with 
HCV within the US 13.  Within the state of South Carolina (SC), surveillance data for 
HBV and HCV infections are routinely reported to the Division of Acute Disease 
Epidemiology (DADE).  Between 2004 and 2008, an aver g  of 661 reports of chronic 
HBV and nearly 20,000 cases of chronic HCV was report d to DADE between the years 
of 2000 and 2005 14. For these same periods, 601 cases of acute HBV and 70 cases of 
acute HCV infections were reported to DADE. It is worthy to note that because new 
HCV case are usually asymptomatic, acute HCV infections are rarely identified or 
reported.  
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Since its discovery in 1981, at least 60 million peo l  have been infected with 
HIV and nearly 25 million have died of AIDS 15. The devastating effect of this pandemic 
continues to pose a significant public health threat particularly in developing countries; 
nevertheless, in developed countries where there is increased access to highly active 
antiretroviral treatment (HAART) for disease management, HIV is no longer the death 
sentence it used to be. In fact, when detected early, the life expectancy of an HIV infected 
individual can be restored to near normal through successful HAART treatment. For this 
reason, HIV is now considered a manageable chronic condition and HIV infected 
individuals on continued therapy have an improved quality of life and are able to live 
long productive lives 16, 17.  HIV infected persons are disproportionately affected by viral 
hepatitis: As of 2009, an estimated 1.2 million persons aged 13 and older residing in the 
US are living with a diagnosis of HIV infection 18. Of these, approximately 20-30% are 
also infected with HCV, while, at least 10% of these HIV-infected individuals are co-
infected with HBV 19, 20. HIV-HBV and HIV/HCV co-infections are highly prevalent 
because of shared risk factors and common routes of transmission 2, 3, 21. HIV modifies 
the natural history of HCV and HBV disease among co-infected individuals; They are 
more likely to develop chronic hepatitis 22 and have an increased risk of liver-related 
mortality and morbidity and suffer life-threatening complication beyond those caused by 
either infection alone 23, 24.  
1.1.2 HBV, HCV and HIV Co-infection in Pregnant Women 
Within the obstetric population, HBV, HCV and HIV co-infections also affect a 
significant number of pregnant women.  Worldwide, HCV infection in pregnant women 
varies from 1% to 8% 25; in the US, the prevalence of HBV infection among women of 
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childbearing age is estimated to be 0.7% 26, while that of HCV is estimated to be around 
1% 27, even though this number is increasing. A recent study in Florida reported an 
increase in the prevalence of HBV infection among pregnant women from 65.4 to 123.5 
per 100,000 births between 1998 and 2007; the same increase was also reported for HCV 
infection in pregnant women 28. In high endemic regions such as sub-Saharan Africa, 
HIV is associated with being HBV- or HCV-positive 29 and among pregnant women, 
higher HIV co-infection rates have been reported to range from 4.1% -8.9% for HBV and 
1.8%-2.1% for HCV 30-33. In the only known cohort of HIV-infected pregnant women 
studied in the US, a 1.5% and 4.9% prevalence was reported for HBV-HIV and HCV-
HIV infections respectively 34. Furthermore, Salihu et al. observed an increased risk of 
HBV and HCV co-infections among HIV/AIDS women when compared to their HIV-
negative counterparts in his study 28. 
In the absence of contaminated blood transfusions, sexual transmission and 
intravenous drug use, a substantial proportion of all chronic HBV cases worldwide are 
attributed to perinatal transmission of HBV. In spite of vaccine availability, infected 
pregnant women remain an important source for HBV chronic infection as children who 
acquire the infection at birth through mother-to-child transmission (MTCT) have up to a 
90% risk of becoming chronic cases themselves 35. Therefore, the CDC recommends 
routine screening for HBV at the time of the first prenatal visit with each pregnancy 
regardless of vaccination or previous testing 36.  
On the contrary, there is no current vaccine for HCV and maternal screening 
during prenatal visits is risk-based and not universal. Similar to HBV, MTCT of HCV is 
a major source of new infections among young children and 80% of perinatal cases that 
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remain HCV RNA-positive after age three develop into chronic HCV cases 37, 38. In HIV 
infected pregnant women, maternal co-infection with v ral hepatitis facilitates the 
transmission of HBV or HCV to newborns 39-42 and children born to co-infected mothers 
have an increased risk of progressing to chronic forms of the disease. Hence, the 
management of HBV and HCV disease during pregnancy, especially among HIV positive 
mothers who are co-infected with viral hepatitis remains an important public health issue 
as reducing perinatal transmission of these disease is crucial to reducing the global 
burden of these diseases 43, 44.   
1.2 Rationale 
There remains a gap in knowledge in how HBV and HCV infection affects pregnancy 
outcomes. In reality, it is not well understood if mono infections with HBV or HCV have 
an adverse impact on pregnancy and perinatal outcomes. Previous studies (see Appendix 
A) from a variety of countries that have investigated his issue have reported inconsistent 
results.  
Majority of the studies that were reviewed used a case-control study design, 
which provides marginal evidence for establishing a “causal relationship” between 
maternal HBV or HCV carrier status and any of the adverse pregnancy or perinatal 
outcomes studied. Furthermore, methodological concerns and limitations noted in these 
studies further weaken the epidemiological evidence that these studies present.  In 
particular, residual confounding, small and non-representative samples of cases, 
information and selection bias is likely to have affected the validity of these studies and 
consequently biased the conflicting results found.    
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 For HBV infected pregnant women, a few studies 45-47 have shown an increased 
risk for preterm delivery, congenital abnormalities and gestational diabetes while others 
studies 44, 48 found no such differences. Similarly, studies on HCV infected pregnant 
women 44, 46, 49, 50 found that the maternal HCV status was associated with a higher risk of 
low birth weight, preterm delivery, congenital anomalies, cesarean delivery, gestational 
diabetes and perinatal mortality. In contrast, other studies 51-54 did not detect significant 
differences in risks associated with these same outcomes (Appendix A). 
Across all studies, hepatitis B surface antigen (HBsAg) assay, an administered 
test used to check for the presence of HBV antibodies, was the measure used to determine 
HBV exposure status.  Being HBsAg positive only indicates active infection, which could 
mean that the mother has either a chronic or acute infection.  Thus, without any 
information on hepatitis B core antibody (anti-HBc) for the study participants that tested 
HBsAg positive at the time of pregnancy, it is hard to distinguish between acute and 
chronic infection status. Moreover, HBsAg provides no indication of past infection or 
previous infection with hepatitis B. In the same way, n anti-HCV test only indicates 
exposure to HCV virus and does not distinguish betwe n someone with an active or 
previous HCV infection; therefore exposure misclassifications error with HBV or HCV 
status may bias the true risk estimates of pregnancy-related outcomes in this population. 
Of equal importance, residual confounding from previous or past exposure to HBV 
infection, which may have been treated or cleared at the time of pregnancy was not 
accounted for in confounders adjusted for in these studies.  
Residual or uncontrolled confounding due to poor and imprecise measurement of 
confounding variables was also a potential problem in these studies. Most importantly, 
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the measurements of drug and alcohol use, also strongly related to poor pregnancy 
outcomes, were not consistently accounted for across all studies. Since drug and alcohol 
abuse is often underreported during pregnancy, it is likely that residual confounding from 
these variables occurred and consequently impacted the study results. Furthermore, 
without adequate control for confounders such as drug and alcohol use, the magnitude of 
any association between HCV/HBV exposure and pregnancy would be inaccurately 
quantified, especially if such an association is small.  Likewise, the effect of HCV and 
HBV viral load during pregnancy was not accounted in all the studies. HCV/HBV viral 
load provides information on the severity of the disease. There is reason to believe that, 
like HIV, women with a well-controlled HCV/HBV viral load during pregnancy may 
have better outcomes than women with high viral loads during pregnancy. 
The highly selective samples used in some studies 47, 51, 52, 55-57 may have reduced 
the generalizability to other populations. Even though a few of the studies used 
population-based samples the remaining studies fromother countries were recruited from 
specialty clinics or single-sites (Appendix A). The sample sizes in these hospital-based 
cohorts were often small (< 50 cases) and therefore, had insufficient power to detect 
associations between pregnancy-related outcomes and HBV or HCV carrier status 
(Appendix A).  Additionally, cases differed greatly on a number of characteristics from 
the selected controls, which reduced their comparability to each other. To illustrate, in a 
case-control study 52 conducted in Ireland, the birth outcomes of 36 Rhesus negative 
women infected with HCV (cases) were compared to Rhesus positive women without 
HCV infection (controls). The authors 52 reported no difference in risk for pre-term 
delivery. Lack of comparability between the cases and controls is a source of bias and 
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may have biased the risk estimate towards the null. I  another case-control study 49 of 
HBV and HCV infected pregnant women in Israel, the authors combined HBV and HCV 
cases in their analysis and found that HBV or HCV carrier status was associated with an 
increased risk for pre-term delivery, perinatal mortality, congenital malformations and 
low birth weight. It is therefore difficult to ascertain whether the observed risk is 
attributable to HCV or HBV infection.   
Lastly, in population-based studies where samples from birth certificates were 
linked to hospital discharge data, the statistical analysis did not account for within-
woman (within-subject) correlations resulting from clusters of women who had more 
than one live birth during the study period. In instances where observations are not 
independent, a more complex regression model such as generalized estimating equations 
(GEE) or a mixed model approach is needed to account f r the correlations within 
subjects. Logistic regression, which assumes independent observations, was incorrectly 
used to analyze the results presented in these studie . Consequently, the standard errors 
obtained are incorrect and the variability is often overestimated leading to inappropriate 
inferences and inflated P values 58, 59.  
Because large numbers of hepatitis infected pregnant women are never identified, 
practice patterns for optimal management of pregnancies from infected HBV or HCV 
mothers are yet to be established. Findings from this study can be used to enhance and 
provide targeted prenatal care services that could significantly improve the quality of 
birthing outcomes for the baby and mother. Furthermore, a better understanding of how 
HCV or HBV impacts pregnancy outcomes could lead to useful prevention strategies. 
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That aside, it is also important to study the magnitude of chronic HCV and HBV 
infection among pregnant populations and HIV/AIDS population in the state of SC, 
possibly representing conditions in the southern pat of the US. A detailed description of 
the disease burden within the prenatal population of SC will provide an impetus for 
prioritizing, and creating targeted interventions. The resulting information is not only 
useful for health planning and disease control, but it can also be used to improve maternal 
and child health locally and nationally at the population level. Additionally, it is 
important to know the geographic and spatial distribu ion of these infections within the 
state would provide valuable knowledge for health department personnel, policy makers 
and health managers to plan and implement interventions and allocate limited health 
resources.  
The primary objective of the proposed project therefore is in threefold focused on 
the descriptive epidemiology and spatial distribution of these infections in SC as well as 
an analytic aspect aimed at elucidating how maternal HBV or HCV status during 
pregnancy affects birth outcomes. 
1.3 Objectives 
Descriptive epidemiologic study 
1. To describe the epidemiology of HBV or, HCV infection and HIV-hepatitis co-
infection among reported female cases in SC between y ars 2004 and 2011. 
Research Question 1.1: What is the prevalence of HBV mono-infection and 
HBV/HIV co-infection in reported females cases in SC?  
10 
Research Question 1.2: What characteristics are associ ted with HBV mono-
infection and HBV/HIV co-infection in reported female cases in SC? 
Research Question 1.3: What is the extent of data agreement between the data 
sources (electronic birth registry and disease surveillance data) used to capture 
maternal hepatitis B surface antigen (HBsAg) infection status during 
pregnancy? 
Research Question 1.4: What is the prevalence of HCV mono-infection, 
HCV/HBV and HCV/HIV co-infection in reported female cases in SC?  
Research Question 1.5: What are the demographic characteristics, patterns of 
CD4+ T-lymphocyte count (CD4), sequence of virus diagnosis and risk factors 
at time of HIV infection among HCV-positive and HCV/HIV positive females 
in SC? 
Geospatial study 
2. To assess the spatial distribution of HCV-infected female cases in SC between 
years 2004 and 2011.  
Research Question 2.1: Given the counts of HCV cases reported in each 
county, do any of the counties have higher counts of disease than what is 
expected?  
Research Question 2.2: What are the demographic characteristics of those areas 
in SC that exhibit high risks for HCV infection? 
Research Question 2.3: Is high drug use activity and other socio-economic or 
environmental factors explain the observed risks for HCV infection in these 
counties? 
11 
Associations of HBV and HCV with birth outcomes 
3. To estimate the association between maternal HBV or HCV status and selected 
pregnancy outcomes for singleton births that occurred in SC between 2004 and 
2011.  
Research Question 3.1: Is being HBV- or HCV-positive during pregnancy 
associated with an increased risk for the following adverse birth outcomes: 
preterm birth, low birth weight, small for gestational age and neonatal intensive 
care admission?  
Research Question 3.2: What is the association of aadverse birth outcome 
with recently diagnosed infected pregnancies and pregnancies from mothers 




HEPATITIS B VIRUS (HBV) AND HBV/HIV  CO-INFECTION AMONG REPORTED 
FEMALE CASES IN SOUTH CAROLINA 
2.1 Abstract 
The aim of this study was to characterize the burden of hepatitis B virus (HBV) and 
human immunodeficiency virus (HIV) co-infection, demographic characteristics and the 
order of HBV/HIV virus diagnosis in women in South Carolina (SC). Additionally, for 
maternal hepatitis B surface antigen positive (HBsAg+) cases, we evaluated the data 
agreement between surveillance data for HBV and HIV, linked to birth registry data for 
years 2004 to 2011. A total of 2,245 female cases of HBV (confirmed and probable) were 
included. Of these, 1 918 (85%) were chronic HBV (cHBV) cases, 325 (15%) were acute 
HBV (aHBV) cases and 2 were perinatal cases. Chronic HBV/HIV co-infection made up 
4.2% of all cases. HIV was diagnosed first in 74% of cHBV/HIV cases with a median 
time to HBV diagnosis of 9 years (range, 2-21). Black women represented 78% of all 
cHBV/HIV cases and heterosexual contact was the most commonly reported mode for 
HIV transmission (58%). At the time of HIV diagnosis, most cases had HIV viral load 
counts >100,000 copies/mL and lived in urban areas of the state. Agreement measures for 
HBsAg+ women reported to surveillance and birth registry records were moderate: 
Cohen’s Kappa = 0.49 (95% CI= 0.44-0.54); percent positive agreement = 49%. An 
increase in efforts to improve screening, reporting a d prevention especially among black
13 
 women is warranted. Also, reports to disease surveillance of infections diagnosed during 
prenatal screening needs to be improved. 
2.2 Introduction 
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) constitute a 
major public health concern globally as both infections are a significant cause of 
morbidity and mortality worldwide. HBV, a leading cause of acute and chronic liver 
disease, is responsible for approximately 1 million international deaths annually 6, 60. It is 
estimated that approximately one third of the world’s population (over two billion 
individuals) have been infected with HBV, and 350 million of these individuals are 
chronically infected. In the United States (US), a country of low HBV endemicity, 
approximately 19 000 new cases of acute HBV infections occurred in 201161; moreover, 
it is believed that between 1.25 and 2 million indivi uals are chronically infected with 
HBV 62, 63. 
Comparatively, HIV-infection is among the top ten causes of death worldwide, 
accounting for over 1.5 million deaths annually 64. Since its discovery in 1981, at least 60 
million individuals have been infected and nearly 25 million have died of acquired 
immunodeficiency syndrome (AIDS) 15. In the post-HAART (highly active antiretroviral 
treatment) era, AIDS-related deaths have continued to decline in developed countries and 
presently, there are more individuals living with HIV as a chronic condition than ever 
before. Based on a 2011 global estimate, there are 37 million individuals living with HIV 
65. 
 Among unvaccinated HIV-infected individuals, HBV co-infection with HIV is 
prevalent because of shared risk factors and common routes of transmission. Of the 1.3 
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million individuals living with an HIV diagnosis in the US as of 2011, at least 10% were 
co-infected with HBV 20. Among co-infected individuals, HIV negatively impacts the 
natural history of HBV disease. These individuals are more likely to develop chronic 
hepatitis 22 and progress to cirrhosis, have an increased risk of liver-related mortality and 
morbidity and suffer life-threatening complications beyond those caused by either 
infection alone 24.  
The burden of HBV mono-infection or co-infection with HIV among US women 
is not well known 66 especially in antenatal populations and among women of 
childbearing age. More precisely, national estimates 12, 67 of HBV prevalence in US 
women are based on data from the National Health and Nutrition Examination Survey 
(NHANES) which excludes high risk populations such as incarcerated and homeless 
persons or minority populations such as Asians and Pacific Islanders in which the disease 
is most common 68. This population-based study overcomes these limitations by 
including all women, especially those at high risk for disease acquisition. 
The aim of this investigation is twofold. First, to describe the characteristics 
associated with HBV mono-infection and HBV/HIV co-infection (demographics, timing 
of infection, risk factors and clinical characteristic ). Second, to assess the extent of 
agreement between two data sources (electronic birth registry and disease surveillance 
data) used to capture maternal hepatitis B surface antigen (HBsAg) infection status 






Three data sources were used for this study: the South Carolina (SC) Health 
Electronic Surveillance System (CHESS) and the enhanced HIV/AIDS Reporting System 
(eHARS) both obtained from the SC Department of Health and Environmental Control 
(DHEC), and the live birth registry records obtained from the SC Budget and Control 
Board, Office of Research and Statistics (ORS). The CHESS database containing all the 
HBV (probable or laboratory-confirmed) cases was linked to eHARS database that 
contains HIV case reports. The resulting dataset was then linked to the birth registry 
records to assess agreement for HBsAg-positive cases reported to CHESS. Institutional 
Review Boards for the SC DHEC, the University of SC Office of Research Compliance 
and the ORS Data Oversight Committee approved this s udy. 
CHESS data 
Acute and chronic HBV infection is mandated by SC law to be reported to DHEC 
and is recorded in CHESS. This database is part of the Centers for Disease Control and 
Prevention (CDC) National Electronic Disease Surveillance System (NEDSS), which has 
been used for disease surveillance and reporting since 2004 69. This web-based 
infrastructure is a passive surveillance system. Following the submission of an initial 
report and case investigation by the local public health department, a DHEC specialist 
reviews the investigation to make sure it meets the surveillance case definitions as set 
forth by the CDC guidelines. A confirmed acute HBV infection was defined as the 
presence of immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) or 
HBsAg positive and evidence of an acute illness with d screte onset of symptoms and 
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jaundice or elevated serum aminotransferase levels (ALT). A probable acute HBV case 
was defined as a positive result for either IgM anti-HBc or HBsAg with missing or 
incomplete clinical information.  A confirmed case of chronic HBV infection was defined 
as HBsAg positive, HBV DNA positive, or hepatitis B e antigen (HBeAg) positive two 
times at least six months apart. Persons testing positive for a single HBsAg or HBV DNA 
or HBeAg test with either a negative IgM anti-HBc or n  IgM anti-HBc test reported 
were defined as probable chronic HBV cases.  CHESS data for cases occurring from 
January 2004 to December 2011 included the following information: reported age, race, 
public health region, year case was reported, case investigation status (probable or 
laboratory confirmed), case zip code, reason for HBV testing and date of diagnosis.  
Enhanced HIV/AIDS Reporting System (eHARS) 
Since 1986, HIV infection has been reportable by name to SC DHEC and 
recorded in eHARS. The quality of data from eHARS exceeds the CDC minimum 
standards on reporting timeliness and completeness 70. The eHARS data for SC female 
cases who were diagnosed with HIV infection or presumed to be living with HIV/AIDS 
by December 2011 included the following: date of birth, race/ethnicity, date of HIV 
diagnosis, residence at time of diagnosis (rural or urban), risk behavior, HIV/AIDS 
disease stage, source of report, CD4+ T-cell counts a d HIV viral load values and dates 
of report.  
Birth registry data 
To determine maternal HBsAg sero-status, the CDC recommends routine testing 
for all pregnant women during each pregnancy, if atrisk for infection during pregnancy 
and at the time of admission for delivery if a prenatal HBsAg test result is not available 
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71. In 2004, the SC’s birth certificate was revised to include maternal HBV and HCV 
infection present/and or treated during pregnancy. For the purpose of this study, the 
following information was used for records of all singleton live births that occurred for 
SC women between the ages of 15 and 49, during January 2004 to December 2011 
inclusive: demographic variables of the mother and infant, date of last menstrual period 
(LMP), pregnancy history, risk factors and infections present during pregnancy, birth 
weight, gestational age and Apgar score of newborn, breastfeeding, presence of 
congenital anomalies and fetal death. 
Data linkage 
ORS created a unique identifier that includes the name, date of birth, social 
security number, gender and race of each case and this unique identifier was used to link 
cases across multiple data sets. Figure 2.1 describ the data linkage process used to 
obtain the final datasets used for analysis. Starting with CHESS data to identify a 
reference group, female records of confirmed and probable HBV cases that were reported 
in SC from 2004 to 2011 was linked to eHARS. This step identified the proportion of 
female cases that were co-infected with HIV. The initial result was HBV and HBV/HIV 
infected female cases reported in SC during the study period with characteristics relevant 
to HIV infection status. 
Subsequently, the resulting data set was linked to the ORS integrated system to 
obtain live birth records over the stated study period. This step further identified women 
who were recorded as being HBsAg-positive during their pregnancy and provided 
additional data on the proportion of HBV and HBV/HIV infected cases that had live 
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births during the study period. Trained statisticians from DHEC and ORS performed the 
record linkage and the final data set contained no personal identifiers.  
Statistical analysis 
We compared demographic and clinical variables from CHESS and eHARS 
across groups of women identified as being co-infected with HIV (cHBV/HIV) or mono-
infected with either acute (aHBV) or chronic HBV (cHBV). For HBV cases with missing 
date of diagnosis, the date case was reported to CHESS was used as an approximate 
diagnosis date instead. Descriptive statistics such as proportions and means were 
employed to summarize the relative frequencies of HBV and HBV/HIV infected cases 
within the entire sample. The Chi-square (χ2) statistic was used to determine if frequency 
distributions of demographic characteristics differed significantly between disease 
groups. Continuous data were expressed as median and range or interquartile range (IQR) 
as appropriate and the Kruskal-Wallis test was used for comparison.  
We used Cohen’s kappa and positive agreement (Pa) 
72 to investigate the degree of 
concordance between HBsAg-positive cases identified through birth certificate data and 
those reported through CHESS. This part of our analysis was restricted to birth data from 
women who had only one singleton pregnancy for the entire study period, as it was 
difficult to ascertain accurate counts from women who had had more than one singleton 
pregnancy over the study period. It was particularly challenging in scenarios where 
women with more than two pregnancies had one pregnancy reported to CHESS during 
which the mother was identified as being HBsAg-positive but for the remaining 
pregnancies she was either identified as being HBsAg-negative or her HBsAg-positive 
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status was not reported to CHESS. All statistical an lysis were performed using SAS 
(version 9.3, SAS institute, Inc.) and DAG_Stat 73.  
2.4 Results 
During the 8-year study period, a total of 2,245 positive HBsAg notifications 
consistent with either chronic or acute HBV infection from 2,223 females were reported 
to CHESS (Figure 2.2). Of the 2,245 cases reported, 1,918 (85%) were chronic HBV 
(cHBV) infections and 325 (15%) were acute HBV (aHBV) infections. Only two 
perinatal cases of HBV were reported for the entire study period. Ninety four percent of 
aHBV were classified as confirmed cases compared to only 65% of cHBV cases met the 
clinical definition for a confirmed case.  
HBV mono-infection individual characteristics  
There were 1,754 cHBV and 295 aHBV reports from mono-infected women 
(Table 2.1). Approximately 281 prevalent cases of HBV were reported each year. Among 
women with available race information, Black and White women represented 20% and 
12% of all HBV cases reported during the study period. Both groups of women were 
relatively young at the time of HBV notification (aHBV: median age=41 years; cHBV: 
median age=37 years). Geographically, over the 8-year p riod, the northeastern region 
(Pee Dee) of the state reported the largest proporti n of aHBV (31%) whereas the central 
region (Midlands) of the state reported the largest proportion of cHBV (28%) cases.   
HBV/HIV co-infection 
Of the 1,918 cHBV cases reported, 164 (8.6%) were co-infected. Among co-
infected cases, 83 (50.6 %) cases were co-infected with hepatitis C virus (HCV) and 81 
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(49.4 %) cases were co-infected with HIV (cHBV/HIV). The results of only the 
HBV/HIV cases are reported here (Tables 2.1 and 2.2).  Black women represented 78% 
of all the cHBV/HIV cases identified and the median age at cHBV notification was 42 
years (range 21-63). Heterosexual contact was the most commonly (57%) reported mode 
for HIV transmission followed by injecting drug use (20%). The median age at HIV 
diagnosis was 35 years (range, 16-62). The majority f women (58%) within this group 
lived in urban areas of the state. HIV was diagnosed first in 62 (75%) of the cHBV/HIV 
co-infected cases and the median time to subsequent HBV diagnosis for these cases was 9 
years (range, 2-21). In 22% of cHBV/HIV co-infected cases, both infections were 
reported in the same year whereas only 4% of co-infected cases had an HBV diagnosis 
reported first. Twenty-nine percent of the cHBV/HIV co-infected women in our study 
had a concurrent diagnosis of HIV infection and AIDS within three months whereas 48% 
were ever diagnosed with an AIDS infection. Triple infection with HBV, HCV and HIV 
was present in a small number (n=7) of cases reportd. A small proportion of aHBV cases 
were also co-infected; 21(6%) cases also reported an infection with HCV whereas 9 (3%) 
cases reported a co-infection with HIV. 
Linkage between CHESS/eHARS and birth registry data 
From the birth registry data, there were 226 894 women with available data on 
infections presented or treated during pregnancy. Our final sample used for assessing 
agreement between CHESS and birth registry included 344 HBsAg-positive women from 
CHESS and 308 (0.13%) HBsAg-positive women identified from the live registry data 
(Figure 2.3). After linkage, the estimated crude prvalence of HBV infection among 
pregnant women within our sample was 0.17% (379/226,894). Only 159 (52%) HBsAg-
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positive mothers were found reported to CHESS while t e remaining 149 (48%) HBsAg-
positive mothers from the birth registry data could not be found in CHESS. Conversely, 
185 (54%) of HBV infected women from CHESS who had a singleton birth were not 
identified as being HBsAg-positive mothers on their birth records even though they were 
reported as being HBV infected prior to their pregnancy.  
There was moderate agreement between CHESS and birth certificate data for 
identifying HBsAg-positive women (Cohen’s k = 0.50 [95% CI= 0.47-0.54]). Percent 
positive agreement was 49%.  
Agreement of HIV cases from the birth data and eHARS could not be ascertained 
because maternal HIV status is not recorded in the birth registry data. Four (6%) out of 
the 68 HIV co-infected women who were of childbearing age had one singleton birth. 
2.5 Discussion 
This study used linked surveillance and birth registry data sources to describe the 
epidemiology of HBV mono-infected and HBV/HIV co-infection among a population-
based sample of women. Overall, we found that approximately 9% of cHBV cases were 
co-infected with either HIV (4.2%) or HCV (4.3 %). The majority of cHBV/HIV co-
infected cases were Black women from urban areas in SC, who self-reported heterosexual 
contact as the main risk factor for HIV transmission and had low first CD4 counts after 
HIV was diagnosed. Women between the ages of 20 and 49 reported the highest 
frequencies of disease occurrence in our study and this observation is consistent with 
other empirical studies 74, 75 conducted in the US that have found that most HBV 
infections occur in young adults with sexual contact being one of the most common 
modes of infection 76. Within the state, the largest proportion of aHBV cases was reported 
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from the northeastern region (Pee Dee), which could ref ect poor vaccination coverage 
for aHBV among women in this region.  
In low endemic regions such as the US, cHBV/HIV co-infection occurs frequently 
with estimated prevalences between 5% and 7% 19. In our study, we observed a moderate 
prevalence of co-infection with HIV/AIDS and HCV among cHBV infected women 
reported to CHESS; 4.2% were co-infected with HIV/AIDS, whereas 4.3% had a co-
infection with HCV. The majority of co-infected women in our study had an HIV 
diagnosis preceding an HBV diagnosis, suggesting that both infections were acquired in 
adulthood and not through perinatal transmission. The 9-year median time between HIV 
diagnosis and a subsequent chronic HBV diagnosis was a striking element in our study. 
Routine HBV testing and immunization is recommended for all HIV-infected persons 
and our finding suggests that there are gaps in compliance with this recommendation. 
This implies that the HIV infected women who were also co-infected with cHBV lived 
with undiagnosed viral hepatitis for long periods of time. Thus, opportunities to counsel 
infected individuals and prevent further transmission were likely to have been missed. 
Additionally, these results indicates a missed opportunity for those with undiagnosed 
HBV to be put on appropriate medication that would treat both HIV and HBV as drug 
resistance and fatal flares of HBV are both potential consequences resulting from 
choosing the wrong therapy without knowledge of HBV status. Our results points to the 
importance of routinely testing HIV infected person for HBV infection and provide 
HBV immunization for sero-negative individuals.  
A large proportion of the HBV/HIV co-infected women in our study presented 
with low CD4 counts and was diagnosed with AIDS almost immediately upon diagnosis. 
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Although we cannot be certain of when these cases contracted HIV, the young median 
age (35 years) and low CD4 counts at HIV diagnosis may suggest long duration of 
infection. A recent study on missed opportunities for HIV testing among HIV infected 
women from SC showed that 73% of cases had missed opportunity visits and among the 
half that were late testers, about 79% were diagnosed with AIDS within a month of 
receiving their HIV diagnosis 77. Because we were unable to assess missed opportunities 
for HIV testing within our sample, we do not know what proportion of HBV/HIV co-
infected women with AIDS also had missed opportunity visits for HIV testing.    
In this study, among mothers who had one singleton birth, we found moderate 
agreement between surveillance data and birth certifi ate data for maternal HBsAg-
positive status. Among the prenatal population in SC, HBsAg infection comprised <1% 
of all cases and the estimated prevalence of HBV infection among pregnant women 
within our study was 0.17%. This was within the reported range of 0.09-0.27% 12, 28, 44, 48 
for US women. Because screening for HBsAg sero-statu  is universally recommended 
during pregnancy and at delivery for high risk women 71, we expect to find most, if not 
all, positive HBsAg cases determined through prenatal screening in the states surveillance 
system as reporting of HBV cases is required by law. When we assessed the degree of 
concordance between CHESS and birth certificate data for mothers who had one 
singleton birth, we discovered that for maternal HBsAg status, CHESS was in moderate 
agreement with birth certificate data and only 52% of HBsAg-positive cases found on the 
birth records were reported to CHESS. Surprisingly, even after excluding HBsAg-
positive mothers who had births before an HBV diagnosis was reported to CHESS, 54% 
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of CHESS cases were designated as being HBsAg negativ  on their birth records and 
52% of HBsAg-positive cases from the birth data were not reported to CHESS.   
Several reasons may explain this observation. First, designated HBsAg-positive 
cases per birth certificate could be false positives that were reported to CHESS and were 
assigned a “suspected” or “not a case” status after fu ther case investigation. 
Unfortunately the extent to which this is true could not be assessed in our data, as only 
probable and confirmed cases were included in study sample. Secondly, we restricted our 
data to only singleton births. HBsAg sero- positive mothers who had plural births and 
reported to CHESS were not included in our analysis.  Nevertheless, because 54% of 
mothers who were confirmed as being HBsAg sero-positive were in CHESS but not 
reported on their birth certificate for that singleton pregnancy raises concerns about the 
quality of data collected for infections present during pregnancy on the birth certificate. 
Historically, validation studies 78, 79 conducted on data from U.S. birth registry data have 
shown it to be a reliable source of information. However, maternal HBV infection 
present/and or treated during pregnancy was recently added as a data item on the revised 
birth certificate and the validity and reliability of this measure has not been formally 
evaluated. Additionally, the high number of HBsAg sero-positive cases not reported to 
CHESS suggests infrequent passive reporting for HBV within the state and an 
opportunity to strengthen ties with clinicians and other key partners engaged in disease 
surveillance reporting. 
The findings in this study are subject to at least three limitations. First, the 
prevalence of HBsAg-positives in our study is very low thus, data agreement results 
should be interpreted cautiously. Secondly, while HBV screening during pregnancy is 
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universally recommended in US, it is likely that screening practices differ across 
providers and this may have resulted in the misclasification of infected but unscreened 
women in the birth certificate data. Furthermore, as the completeness of surveillance data 
from CHESS is unknown, the data presented here is not representative of all the HBV 
infected cases that occurred over the study period. M reover, our data on HBV and HIV 
diagnosis date reflects an approximate time for when t se conditions were detected and 
subsequently reported. We cannot determine when the eit r infections occurred or 
confirm the order of infection for those women who were co-infected. Finally, CHESS 
data did not capture several key demographic variables, most especially detailed race 
information and HBV risk factor data, that could have strengthened our description of 
this population.  
In spite of these limitations there are strengths to our study.  This study offers the 
first description of HBV and HBV/HIV disease burden within the SC female population. 
Moreover, this study employs a rich variety of data sources and uses a sequential record 
linkage process that links reported cases of HBV to birth records. Lastly, being able to 
assess how birth data for maternal HBsAg status compares to reported HBV surveillance 
data identifies opportunities to enhance and strenghen disease reporting. 
In summary, the prevalence of HBsAg infection among pregnant women was 
within the reported range of previous estimates (0.09-0.27%). HIV and HCV co-infection 
within this population was substantial and there was moderate agreement between 
surveillance and birth registry data reported for maternal HBsAg status. HIV co-infected 
women were largely young black adults who had their HBV diagnosed almost a decade 
later and lived in urban areas. An increase in efforts to improve screening, reporting and 
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prevention especially among black women is warranted. Our results also suggest that 
reports of infections found during prenatal screening to the disease surveillance needs to 
be improved. More training should be provided for birth record abstractors to promote 
accurate reporting of this data to surveillance. Clinicians can educate mothers by 
explaining the importance of data and its widespread use nationally to enhance reporting 
accuracy. More importantly, using the birth registry data by itself to identify HBsAg 
positive women may not be adequate and future studies can benefit from using both 
surveillance data and birth data in identifying HBsAg-positive women.   
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Table 2.1- Demographics of hepatitis B virus (HBV) and HIV co-infected female cases in South 
Carolina reported to CHESS and eHARS between 2004 and 2011 








n (%)  
 
HBV-related variablesa P-value 
Number of cases  2132 295 1754 83  
Age at HBV, years, median 
(range) 38 (1-91) 41 (1 - 85) 37 (1 - 91) 42 (21 - 63) <0.001b 
≤20 115 (5) 3 (1) 112 (6) - <0.001
c 
20-29 503 (24) 46 (16) 450 (26) 7 (8)  
30-39 508 (24) 86 (29) 395 (23) 27 (33)  
40-49 410 (19) 83 (28) 301 (17) 26 (31)  
50-59 311 (15) 43 (15) 248 (14) 20 (24)  
≥60 267 (13) 30 (10) 234 (13) 3 (4)  
    Missing  4 (1) 14 (<1) 0  
Year of HBV diagnosis     <0.001
c 
2004 379 (18) 65 (22) 301 (17) 13 (16)  
2005 342 (16) 66 (22) 270 (15) 6 (7)  
2006 321 (15) 42 (14) 265 (15) 14 (17)  
2007 261 (12) 24 (8) 220 (13) 17 (20)  
2008 235 (11) 33 (11) 191 (11) 11 (13)  
2009 230 (11) 23 (8) 197 (11) 10 (12)  
2010 175 (8) 22 (7) 145 (8) 8 (10)  
2011 189 (9) 20 (7) 165 (9) 4 (5)  
Race      
Black 420 (20) 81 (27) 274 (16) 65 (78) <0.001
c 
White 253 (12) 58 (20) 180 (10) 15 (18)  
Other 174 (8) 11 (4) 160 (9) 3 (4)  
Missing 1285 (60) 145 (49) 1140 (65) 0  
Hepatitis B vaccine received 
indicator     
 
No - 150 (51) - -  
Yes - 13 (4) - -  
Missing - 132 (45)    
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Table 2.1- Demographics of hepatitis B virus (HBV) and HIV co-infected female cases in South 
Carolina reported to CHESS and eHARS between 2004 and 2011 (cont’d.) 








n (%)  
 
HBV-related variablesa P-value 
DHEC region     <0.001c 
Low country 501 (24) 61 (21) 424 (24) 16 (19)  
Midlands 594 (28) 75 (25) 494 (28) 25 (30)  
Pee Dee 400 (19) 90 (31) 285 (16) 25 (30)  
Upstate 435 (20) 38 (13) 388 (22) 9 (11)  
Missing 202 (9) 31 (11) 163  (9) 8 (10)  
Case classification      
Confirmed 1457 (68) 276 (94) 1135 (65) 46 (55) <0.001c 
Probable 675 (32) 19 (6) 619 (35) 37 (45)  
HIV, human immunodeficiency virus; cHBV, chronic hepatitis B virus; aHBV, acute hepatitis B virus; 
CHESS, Carolina’s health electronic surveillance system; DHEC, department of health and 
environmental control. 
*Percentages may not equal to 100 because of rounding. 
aHBV-related variables were obtained from CHESS surveillance database. 
bKruskal Wallis p-value was calculated for continuous values.  
cChi-square p-value was calculated for categorical values. 
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Table 2.2 - Characteristics of chronic hepatitis B and HIV co-infected female cases in South 
Carolina reported to CHESS and eHARS between 2004 and 2011 
 Co-infection 
HIV-related variablesa cHBV/HIV N (%) 
Number of cases 83 
Year of HIV diagnosis  
1985-1989 3 (4) 
1990-1994 15 (18) 
1995-1999 23 (28) 
2000-2004 16 (19) 
2005-2009 21 (25) 
≥ 2010 5 (6) 
Age at HIV, years, median (range) 35 (16-62) 
≤20 5 (6) 
20-29 27 (33) 
30-39 19 (23) 
40-49 22 (27) 
50-59 9 (11) 
≥60 1 (1) 
Timing of HIV-HBV diagnosis  
HIV reported first 62 (75) 
HIV and HBV reported togetherb 18 (22) 
HBV reported first 3 (4) 
HIV disease stage at diagnosis  
HIV only 19 (23) 
HIV and later AIDS 40 (48) 
HIV and AIDS diagnosed simultaneously 24 (29) 
HIV transmission category  
Injecting drug use 17 (20) 
Heterosexual 47 (57) 
No identified riskc 18 (22) 
Otherd 1 (1) 
  
30 
Table 2.2- Characteristics of chronic hepatitis B and HIV co-infected female cases in South 
Carolina reported to CHESS and eHARS between 2004 and 2011(cont’d.) 
 Co-infection 
HIV-related variablesa cHBV/HIV N (%) 
Source of HIV report  
County health department 18 (22) 
Hospital 19 (23) 
Group practice 12 (14) 
Other statee 11 (13) 
Otherf 5 (6) 
Unknown 18 (22) 
Residence at time of HIV diagnosis  
Urban 48 (58) 
Rural 19 (23) 
Missing 16 (19) 
CD4+ percentage  
No. of women with data available 81 
0-25% 57 (70) 
26-40% 21 (26) 
≥40% 3 (4) 
First viral load group  
No. of women with data available 76 
≤ 10,000 copies/mL 25 (33) 
> 10,000 copies/mL 51 (67) 
First CD4+ count  
No. of women with data available 81 
Median (IQR) cells/mm2 189 (58-494) 
First viral load  
No. of women with data available 76 
Median (IQR) copies/mL 28561 (4762-114635) 
HIV, human immunodeficiency virus; cHBV, chronic hepatitis B virus; IDU, injecting drug use; mL, 
milliliter; CD4, cluster of differentiation 4; 
*Percentages may not equal to 100 because of rounding. 
aThese variables were obtained from the enhanced HIV/AIDs reporting system (eHARS). 
bHIV and HBV were diagnosed and reported in the same year. 
cAdults with no risk factors reported (n=4) or no identified risk factors (n=14). 
dOther risk category includes heterosexual who had sexual intercourse with a high-risk individual (e.g., 
IDU, male bisexual, transfused individual, HIV-positive individual) 
eOther state includes reports from other states. 












Figure 2.2 Sample population and flow for hepatitis B virus (HBV) female cases from CHESS linked with HIV data 







Data linkage CHESS/eHARS  
1 556  HBsAg-positive women 
 
Birth Registry Data 
226 894 women with one pregnancy 
 
308 HBsAg-positive women 
159 reported to 
CHESS 
149 not reported to 
CHESS 
379 had one singleton birth 
Excluded 35 women that 
had births occur before 
HBV diagnosis 
344 HBsAg-positive  
with a live birth 
185a HBsAg-negative on 
birth certificate 
a 9 were acute HBV reports and 177 were chronic cases 
Figure 2.3 Sample population for hepatitis B virus (HBV) female cases from CHESS/eHARS linked with birth egistry; 




HEPATITIS C VIRUS (HCV), HCV/HEPATITIS B VIRUS (HBV) AND HCV/HIV 
CO-INFECTION AMONG REPORTED FEMALE CASES IN SOUTH CAROLINA 
3.1 Abstract 
Few data exist on the magnitude of Hepatitis C virus (HCV) mono-infection, and its co-
infection with hepatitis B virus (HCV/HBV) and human immunodeficiency virus 
(HCV/HIV) within the US female population. This study describes the burden of HCV, 
HCV/HBV and HCV/HIV co-infection, demographic characteristics and the order of 
HCV/HIV virus diagnosis in women in South Carolina (SC). The study used a linked 
dataset of surveillance data that was reported fromHCV-, HBV- and HIV-infected 
female cases that occurred in SC between 2004 and 2011. We identified a total of 10,208 
HCV-positive reports. Ninety-five percent were mono-i fected with HCV, followed by 
4% who were co-infected with HCV/HIV and 1% with HCV/HBV infection. HCV 
mono-infected cases overall were predominantly middle-aged White women. However, 
after stratifying our results by age for those with available race information (40%), we 
observed an increase over the study period in the number of HCV infections reported for 
White adolescents and young adults aged 15-25 yearsold. HCV/HIV co-infected cases 
tended to be Black middle-aged women from urban areas who reported either intravenous 
drug use (IDU) or heterosexual contact as their main risk factor for HIV transmission.
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 HIV was diagnosed first in 79% of HCV/HIV co-infect d cases and 62% of HCV/HBV 
co-infected cases had both infections reported within the same year. Our findings suggest 
a need for resources to be directed at improving screening and prevention efforts among 
middle-aged White women, Black women and young persons between the ages of 15 and 
25 years.  
3.2 Introduction 
Hepatitis C virus (HCV) infection is the most common chronic blood-borne 
infection in the United States (US) and remains a global leading cause of liver-related 
morbidity and mortality 80, 81. The estimated number of HCV-infected individuals 
worldwide is staggering. Between 130-170 million, 2-3% of the world’s population, are 
chronically infected with HCV 82. In the US, taking into account institutionalized, 
incarcerated and homeless persons, there are at least 3.5 million individuals who are 
infected with chronic HCV 83, 84. In one recent study, when active military service 
personnel, nursing home residents and immigrants were accounted for, as many as 5.2 
million individuals in the US were reported to be living with chronic HCV infection 13.  
Among individuals infected with human immunodeficiency virus (HIV), co-
infection with HCV is very common as these two infections share common risk factors 
for transmission. Of the estimated 1.3 million HIV-infected Americans, about 25% are 
co-infected with HCV and among HIV patients who have  history of either intravenous 
drug use (IDU) or hemophilia, HCV/HIV co-infection rates ranges from 70 to 95% 20, 21 
19. For individuals living with both viruses, HIV adversely affects the natural history of 
HCV disease 85, 86. Thus, co-infection is associated with severe disease, high HCV viral 
loads, a faster progression to liver disease and an increased rate of decompensated liver-
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related mortality3, 23, 24, 85 87, 88. These adverse clinical outcomes are also seen amog 
those co-infected with both HCV and hepatitis B virus (HBV). Compared to a single 
hepatitis infection, co-infection with HCV and HBV is associated with a higher 
prevalence of liver cirrhosis, liver decompensation as well as an increased risk of 
developing liver cancer 89-91. 
In order to evaluate the burden and trends of HCV adequately, HCV prevalence 
should be stratified by age, ethnicity and gender 82. However, unanswered questions exist 
concerning the epidemiology of HCV, HCV/HIV and HCV/HBV infection within the 
female population. Specifically, for women in their childbearing years and those who are 
pregnant, the prevalence of HCV has not been well-studied 28. Estimates from the 
National Health and Nutrition Examination Survey (NHANES) estimates HCV 
prevalence in US women at close to 1% 27, 84, whereas estimates using US birth data have 
yielded prevalence rates that fall between 0.06 and 0.2% 28, 44, 50. Yet, these data do not 
take into account certain populations, such as homeless or incarcerated persons, that are 
at high risk for HCV infection 13. Additionally, the completeness of reporting HCV 
infection on the US birth certificate is unknown and because universal screening of HCV 
during pregnancy is not mandatory, ascertainment bias could likely influence these HCV 
prevalence estimates from birth certificates 50. 
Surveillance data offer an alternative opportunity to overcome some of these 
limitations through the use of a population-based sample. Beyond being a valuable 
epidemiologic tool for descriptive analysis, surveillance data avoids some biases found in 
population surveys in that data are reported from all sources, including hard to reach 
populations 92. To the best of our knowledge, there are no studies that have used 
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surveillance data to characterize the burden of HCV, HCV/HIV and HBV-HCV infection 
within a female population. 
In this study, we used data collected through South Carolina’s (SC) viral hepatitis 
and HIV/AIDS surveillance system to report on the pr valence, demographic 
characteristics, patterns of CD4+ T-lymphocyte count (CD4), sequence of virus diagnosis 
and risk factors at time of HIV infection among HCV-positive females in SC.  In our 
previous study 93, we described characteristics associated with HBV and HBV/HIV co-
infection and assessed the extent of agreement between the electronic birth registry and 
disease surveillance data.  
3.3 Methods 
Data sources 
Two data sources were obtained from the SC Department of Health and 
Environmental Control (DHEC) and used for this study: the South Carolina (SC) Health 
Electronic Surveillance System (CHESS) and the enhanced HIV/AIDS Reporting System 
(eHARS). The CHESS database containing all the HCV and HBV (probable or 
laboratory-confirmed) cases was linked to eHARS datab se that contains HIV case 
reports. Approval was received from SC DHEC and the University of SC Office of 
Research Compliance. 
CHESS data 
In SC, all positive laboratory results (confirmed and probable) indicating HCV 
infection are required by law to be reported to SC DHEC and are recorded in CHESS 69. 
This web-based infrastructure is a passive surveillance system and is part of the Centers 
for Disease Control and Prevention (CDC) National Electronic Disease Surveillance 
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System (NEDSS) which has been used for disease survillance and reporting since 2004 
94 . A trained DHEC specialist reviews all positive HCV tests recorded in CHESS to 
ensure that each notified case meets the case definition for HCV as set forth by the CDC 
guidelines. In accordance with these surveillance guidelines, a confirmed chronic HCV 
case (past or current infection) was defined as a positive anti-HCV assay with either a 
positive nucleic acid test (NAT) result or a positive recombinant immunoblot assay 
(RIBA) test to further confirm HCV infection. Conversely, all positive anti-HCV assay 
reports where neither a NAT nor RIBA test was conducted or reported to SC DHEC and 
did not meet the case definition for an acute HCV case were defined as probable chronic 
HCV cases.  Because no laboratory distinction can be made between a previous or 
current infection and includes about 20% of persons who resolved their infections, 
confirmed chronic HCV cases represent “past or present” HCV infection 95. 
For our analysis, all confirmed or probable female cases with a report date 
between January 1st 2004 and December 31st 2011 were extracted from CHESS along 
with demographic data on the reported age, race and zip code. To identify HCV/HBV co-
infected cases, the same inclusion criteria were applied to extract HBV infected cases 
from CHESS. This data were described elsewhere 93.  
Enhanced HIV/AIDS Reporting System (eHARS) 
HIV is a mandatory reportable disease in SC and since 1986, all newly identified 
cases of HIV infection who are residents of SC has been reported to the eHARS. 
Recorded in the eHARS database are demographic variables, CD4 counts and HIV viral 
loads.  Based on a routine assessment of the database for accuracy and completeness, the 
quality of data from eHARS exceeds the CDC minimum standards on reporting 
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timeliness and completeness; 95% within six months of a diagnosis and 98% 
completeness based on comparison with other data sources [SC DHEC, unpublished data, 
2010]. For our analysis, female cases of HIV/AIDS who were reported to eHARS by 
December 2011 were eligible to be selected for potential linkage to CHESS cases.  
 
Data linkage 
A trained statistician from DHEC performed the data linkage for this study. Using 
probabilistic matching methods, HCV-positive cases from CHESS were linked to HIV 
positive records from eHARS. Each record was matched on gender, name, race, social 
security number and date of birth. After linkage thfinal dataset contained no identifiers. 
Statistical analysis 
We compared demographic differences for HCV- and HIV-related variables 
across groups of women identified with HCV mono-infection, HCV/HIV or HCV/HBV 
co-infection over the 8-year study period. Frequencies and percentages for each level of 
categorical variables were calculated and the Chi-square (χ2) statistic was used for 
comparison. Continuous data such as age and CD4 counts were expressed as median and 
range or median and interquartile range (IQR) as appropriate.  
We determined the sequence of virus diagnosis for both HCV/HIV and 
HCV/HBV co-infected cases by obtaining the differenc  in time between the year either 
HIV or HBV was reported and the year HCV was reported. The prevalence of HBV 
infection among those infected with HCV was calculated as the proportion of HCV cases 
with a positive hepatitis B surface antigen report (HBsAg) in CHESS during the study 
period. HBsAg positive cases from CHESS included probable or confirmed cases that 
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were either acute or chronic HBV infections. All data were analyzed using SAS (version 
9.3, SAS Institute Inc.) and R statistical program 96. 
3.4 Results 
A total of 10,208 reports from female cases of HCV were received in CHESS 
over the 8-year study period (Figure 3.1). Of these r ports, 11 (<1%) were acute HCV 
cases and the remaining 10,197 were chronic HCV cases. Our analysis was limited to the 
portion of the sample that had a chronic HCV infection (Table 3.1 and 3.2).  
HCV mono-infection 
Of the total 10,197 chronic HCV cases reported, 9,664 (97%) were mono-infected 
and of these, 8,469 (88%) cases met the clinical definition for a confirmed case. The 
median age at HCV notification was 48 years (range 1-79 years). Forty percent (3,856) of 
mono-infected cases had available race information. Among these, 27% were White and 
12% were Black. An average of 1,208 prevalent cases were reported each year with the 
western (Upstate) and central (Midlands) regions of the state reporting the largest 
proportions (26% and 21%) of monoinfected cases respectively. 
When the age distribution for the number of monoinfected cases were stratified by 
race (for those with available race information) and compared for years 2004 and 2011, 
we noted a difference by race (Figure 3.2). For White females, the mean age decreased 
from 45 years in 2004 to 44 years in 2011 while the variance increased from 139.6 in 
2004 to 195.7 in 2011. For Black females, the mean age increased from 50 years in 2004 





HCV/HIV co-infection prevalence in this sample was 4% (95% CI: 3.9% - 4.7%) 
and the median age at the time of HCV diagnosis was 48 years (range, 18-75 years). The 
majority of co-infected cases were Black (76%) whereas 21% were White. Almost half of 
HCV/HIV co-infected cases (46%) reported IDU as the main risk factor for HIV 
transmission and this was followed by 38% of cases that reported heterosexual exposure 
as a risk factor. The majority of cases (59%) residd in urban areas whereas over 50% of 
the HIV reports were from hospitals and county health departments. HIV was diagnosed 
first in 340 (79%) cases and among these cases, the median time to subsequent HCV 
diagnosis was 9 years (range, 1-23 years). Although 16% had both infections reported in 
the same year, 5% of HCV/HIV cases had an HCV diagnosis reported first. AIDS disease 
stage was diagnosed in 42% of HCV/HIV cases whereas only 34% were HCV/HIV cases 
without AIDS. At the time of HIV presentation, the median age was 40 years (range, 16-
69 years), and the median CD4 cell count and viral load were 307 cells/µL (IQR 156-528 
cells/µL) and 14,000 copies/mL (IQR 1,780-73,860 copies/mL), respectively.  
HCV/HBV co-infection 
There were 101 (7%) cases of HCV that were co-infected with HBV. Seven of 
these cases, also had an infection with HIV, i.e., these individuals had a triple infection 
with HCV, HIV and HBV. Of the 94 cases that remained, 20 (21%) were an acute HBV 
infection while 74 (79%) had a chronic infection with HBV. At the time HCV was 
reported, the median age was 49 years (range, 21-79) and 84% met the clinical definition 
for a confirmed HCV case. When we considered the 40 (43%) cases with available race 
information, notifications from White women made up the largest proportion (26%). 
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HCV and HBV infections were reported within a year of each other in majority (62%) of 
the cases and only 16% had their HBV infection repoted first.  
3.5 Discussion 
Our data showed that for the 40% of HCV mono-infected cases with available 
race information, middle-aged White women were predominant and who were most 
likely to reside in the western (Upstate) and central (Midlands) regions of the state. These 
findings are consistent with what is already known about HCV infection from national 
data. The NHANES data from 1999-2002 showed that anti-HCV prevalence was highest 
among individuals between the ages of 40 and 49 years 84. Additionally, a recent 
NHANES study using data from 2001-2010 revealed that more than two-thirds (70.1%) 
of US sero-prevalent HCV cases belonged to 1945-196 birth cohort 97. In our study, 
65% HCV mono-infected cases were in the 40-59 years age group that corresponds to 
1952-1970 birth cohort. Within this cohort, persons born between 1945 and 1964 were 
between the ages of 40 and 59 in 2004. From the NHAES data, even though the 
national prevalence of females infected with HCV is estimated to be around 1.1%84, this 
data covers only non-institutionalized persons meaning that active military personnel, 
incarcerated, homeless, hospitalized individuals are excluded from this estimate 13.  
Furthermore, epidemiologic data on HCV mono-infection and HCV/HBV or HCV/HIV 
co-infection in female populations are rare. Because women constitute a large proportion 
of the total adult population, monitoring HCV prevalence trends, as has been previously 
done with the HIV epidemic, is useful for assessing the extent of HCV infection within 
the general population. To the best of our knowledge, this study represents one of the 
largest cohorts of HCV-positive women whose co-infection status was identified using 
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surveillance data.  
Our findings add to previous evidence about HCV infection to reveal that there 
has been a substantial increase from 2004 to 2011 in the number of HCV infections in 
adolescents and young adults between the ages of 15 and 25 years. When we compared 
the age distribution for cases reported in 2004 and those reported in 2011, we observed an 
increase in the variance for 2004 and 2011. Similar observations were also reported from 
three studies 1, 98, 99 that used HCV surveillance data from Massachusetts, New York and 
Wisconsin. In these studies, the young adults were predominantly White residents in rural 
and urban communities and IDU was associated with the observed increase 1, 98, 99. In our 
study, when we looked at age distribution by race for cases with available race 
information, the results for White women appeared to be evident than those for Black 
women. It should be noted that since race information was missing for over 57% of 
reported HCV cases, caution should be applied to the interpretation of these results. 
Furthermore, since we lacked data on HCV risk history f r these cases reported, we were 
unable to assess if IDU explained the observed increase in the number of HCV cases 
reported for young adult and adolescents in 2011. 
HCV/HIV co-infection was present in 4% of all the chronic HCV cases. These 
were primarily Black middle-aged women from urban communities in SC who had their 
HIV infection identified first, reported IDU as the main risk factor for HIV transmission 
and had a median CD4 count of 307 cells/mm2 (IQR 156-528 cells/mm2) at baseline 
testing. Our results are comparable to findings from a US study that used HIV-infected 
women visiting a prenatal clinic and reported an HCV/HIV prevalence of 4.9% 34. 
Conversely, other US epidemiological studies on HCV/HI  co-infection have yielded 
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prevalences between 16% and 36% 100-102, although these studies were conducted 
primarily in HIV-positive cohorts that were disproportionately male. We obtained the 
number of women reported to be living with HIV/AIDS in SC as of December 2011 to 
determine the proportion of HIV infected women that are co-infected with HCV. We 
estimated that 9.4% (432/4,578) of HIV positive women are co-infected with HCV/HIV.  
Because of shared routes of transmission for both HCV and HIV infections, it is 
not surprising that in our study, IDU and heterosexual contact were the most common 
self-reported HIV risk factor. HIV was diagnosed first in 79% of the cases and the 9-year 
median time between HIV and a subsequent chronic HCV diagnosis is a significant 
finding. CDC and the US Preventive Services Task Force recommend HCV screening in 
HIV infected individuals at the time of entry into health care but does not recommend a 
frequency after baseline screening. Our finding here could help make the case for 
recommending routine HCV screening amongst HIV-positive individuals, especially 
those known to be injection drug users. Early detection of HCV infected individuals can 
prevent further transmission, help select the appropriate medication for treatment and 
consequently reduce HCV-related mortality within this population.  
One explanation for why HCV was reported much later in the majority of our 
HCV/HIV co-infected cases is that HIV increases susceptibility of infected women to 
sexually acquired HCV 103, thus, it is likely the HCV infection was acquired as a 
consequence of being infected with HIV. In one cross-sectional study among HIV-
positive women reporting no history of IDU, heterosexual contact with a male drug 
injector was associated with being HCV positive 104. Conversely, in a Canadian study that 
used surveillance data from both genders, the authors reported HCV diagnosed first in 
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52% of their cases and this was independently associated with IDU behavior 105. 
Although we were unable to assess the extent to which IDU or heterosexual contact was a 
risk factor for HCV transmission in this study, it is likely that both heterosexual contact 
and IDU were risk factors in HCV acquisition. 
Lastly, 1% of our cases were co-infected with HCV/HBV and this estimate was 
comparable to an estimate of 1.4% recently reported by Tyson et al. 106. In other US 
studies 27, 107, 108 higher prevalences for past HBV exposure among HCV cohorts have 
been reported to range from 25%-65%. Our HCV/HBV co-infected women had their 
HBV diagnosed first and this is likely due to universal screening practices for HBV 
infection during obstetric care. In contrast to Bini et al. 107 who reported HCV/HBV co-
infection to be highest amongst individuals with age less than 40 years, we found that 
67% of our HCV/HBV cases were between the ages of 40 and 59 years old.  
Our findings here are limited because the completeness of HCV surveillance data 
from CHESS is unknown. Also, our HCV data is biased towards persons more likely to 
have health insurance and to be receiving health care. Thus, this data may not be a 
representative sample of all the HCV-infected cases that occurred over the study period. 
We could not estimate the prevalence of HCV infection in our study due to the lack of a 
true denominator for our surveillance cases. Furthermore, our data on diagnosis date for 
HCV, HBV and HIV infection reflects approximate times for when these conditions were 
detected and subsequently reported. However, we cannot determine when these infections 
occurred or confirm the order of either HCV/HIV or HCV/HBV infection for those who 
were co-infected. Finally, several missing data from key demographic variables, such as 
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race/ethnicity and HCV risk factor, in the CHESS datab se may have weakened our 
description of this population.  
 Our study offers the first description of HCV/HIV and HCV/HBV co-infection 
prevalence within the SC female population. The use of statewide surveillance data to 
ascertain the co-infection status of HCV-infected fmale cases is another strength of this 
study. Finally, our study represents one of the largest cohorts of HCV-infected females in 
the US. Characteristics of these HCV mono-infected an  co-infected women can be used 
to target screening and prevention efforts at the local and state level. 
 In summary, our results appear to be consistent with hat is already known about 
HCV infection. HCV mono-infected cases were predominantly middle-aged White 
women whereas those co-infected with HCV/HIV were largely Black middle-aged 
women from urban areas who reported either IDU or heterosexual contact as their main 
risk factor for HIV transmission. There was a substantial increase in the number of HCV 
infections reported for adolescents and young adults be ween the ages of 15 and 25 years. 
Our co-infection prevalence was close to the reported ange of previous estimates of 
4.9%- 36% and 1.4%-65% for HCV/HIV and HCV/HBV respctively. 
The findings suggest a need for resources to be directed at improving screening 
and prevention efforts among Black and White middle ag d women and most especially, 
in young persons between the ages of 15 and 25 years. Over three-thirds of the HCV/HIV 
infected women in our study belonged to the 1945 to 1965 birth cohort. These individuals 
benefit from combined testing for HIV and HCV infections. Not only will this approach 
be cost-effective, it can lead to the timely identification of HCV/HIV co-infected 
individuals. HIV-infected individuals with IDU as a risk factor or heterosexual contact 
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with male IDU should be routinely screened for HCV because of the risk of ongoing 
exposure to HCV.  Because HCV risk behavior and detailed race information were 
unavailable for analysis in our HCV surveillance data, initiatives to fund and improve 
HCV case reporting data are warranted.
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Table 3.1- Demographics of hepatitis C (HCV), hepatitis B virus (HBV/HCV) and HIV co-
infected female cases in South Carolina reported to CHESS and eHARS between 2004 and 2011 
 Co-infection Mono-infection  






n (%) P-valuec 
Number of cases 94 432 9664  
Age at HCV, years, median (range) 49 (21 - 79) 48 (18 - 75) 48 (1 - 99)  
≤20 0 1 (<1) 136 (1) <0.001 
20-29 5 (5) 15 (3) 755 (8)  
30-39 13 (14) 57 (13) 1229 (13)  
40-49 33 (35) 190 (44) 3157 (33)  
50-59 30 (32) 145 (34) 3113 (32)  
≥60 12 (13) 22 (5) 1219 (13)  
   Missing 1 (1) 2 (<1) 55 (<1)  
Year HCV was reported    0.018 
2004 13 (14) 54 (13) 1014 (10)  
2005 20 (21) 60 (14) 1385 (14)  
2006 13 (14) 65 (15) 1447 (15)  
2007 14 (15) 62 (14) 1299 (13)  
2008 9 (10) 70 (16) 1293 (13)  
2009 12 (13) 50 (12) 1048 (11)  
2010 8 (8) 47 (11) 1054 (11)  
2011 5 (5) 24 (6) 1124 (12)  
Race     
Black 13 (14) 330 (76) 1184 (12) <0.001 
White 24 (26) 92 (21) 2562 (27)  
Other 3 (3) 7 (2) 110 (1)  
    Missing 54 (57) 3 (1) 5808 (60)  
Case classification     
Confirmed 79 (84) 381 (88) 8469 (88) 0.53 
Probable 15 (16) 51 (12) 1195 (12)  
DHEC region     
Low country 21 (22) 91 (21) 1752 (18) <0.001 
Midlands 30 (32) 134 (31) 2073 (21)  
Pee Dee 13 (14) 82 (19) 1706 (18)  
Upstate 15 (16) 59 (14) 2530 (26)  
Missing 15 (16) 66 (15) 1603 (17)  
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Table 3.1- Demographics of hepatitis C (HCV), hepatitis B virus (HBV/HCV) and HIV co-
infected female cases in South Carolina reported to CHESS and eHARS between 2004 and 2011 
(cont’d.) 
 Co-infection Mono-infection  






n (%) P-valuec 
Timing of HCV/HBV diagnosis     
HBV reported first 16 (16)    
HCV and HBV reported concurrentlyb 63 (62)    
HCV reported first 22 (22)    
HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; CHESS, Carolina’s 
Health Electronic Surveillance System; DHEC, Department of Health and Environmental Control 
*Percentages may not equal to 100 because of rounding. 
aHBV-related variables were obtained from CHESS surveillance database. 
bHBV and HCV were reported to CHESS within the same year of diagnosis. 




Table 3.2- Characteristics of hepatitis C and HIV co-infected female cases in South Carolina 
reported to CHESS and eHARS between 2004 and 2011 
 Co-infection 
HIV-related variablesa cHCV/HIV (N %) 
Total number of cases 432 
Year of HIV diagnosis  
1985-1989 26 (6) 
1990-1994 81 (19) 
1995-1999 96 (22) 
2000-2004 108 (25) 
2005-2009 92 (21) 
≥ 2010 29 (7) 
Age at HIV, years, median (range) 40 (16-69) 
≤20 11 (3) 
20-29 56 (13) 
30-39 144 (33) 
40-49 154 (36) 
50-59 56 (13) 
≥60 9 (2) 
Timing of HIV-HCV diagnosis  
HIV reported first 340 (79) 
HIV and HCV reported togetherb 67 (16) 
HCV reported first 25 (5) 
HIV disease stage at diagnosis  
HIV only 149 (34) 
HIV and later AIDS 181 (42) 
HIV and AIDS diagnosed 
simultaneously 
102 (24) 
HIV transmission category  
Injecting drug use 197 (46) 
Heterosexual 166 (38) 
No identified riskc 68 (16) 
Otherd 1 (<1) 
Residence at time of HIV diagnosis  
Urban 254 (59) 






Table 3.2. Characteristics of hepatitis C and HIV co-infected female cases in South Carolina 
reported to CHESS and eHARS between 2004 and 2011 (cont’d.) 
 Co-infection 
HIV-related variables cHBV/HIV (N%) 
Source of HIV report  
County health department 97 (22) 
Hospital 125 (29) 
Group practice 49 (11) 
Other statee 54 (13) 
Otherf 28 (6) 
Unknown 79 (18) 
CD4+ percentage  
No. of women with data available 424 
0-25% 258 (60) 
26-40% 124 (29) 
≥40% 42 (10) 
First viral load group  
No. of women with data available 381 
≤ 10,000 copies/mL 174 (40) 
   >10,000 copies/mL 207 (48) 
First CD4+ count  
No. of women with data available 427 
median (IQR) cells/µL 307 (156-528) 
First viral load  
No. of women with data available 381 
median (IQR) copies/mL 14000 (1780-73860) 
HIV, human immunodeficiency virus; HCV, hepatitis C virus; HBV, hepatitis B virus; CD4, cluster of 
differentiation 4; mL, milliliter; IDU, injecting drug use. 
*Percentages may not equal to 100 because of rounding. 
aThese variables were obtained from the enhanced HIV/AIDS Reporting System (eHARS). 
bHIV and HCV were diagnosed and reported in the same year. 
cAdults with no risk factors reported (n=17) or no identified risk factors (n=51). 
dOther risk category includes heterosexual who had sexual intercourse with a high-risk individual (e.g., 
IDU, male bisexual, transfused individual, HIV-positive individual) 
eOther state includes reports from other states. 






Figure 3.1 Sample population and flow for h
HIV data from eHARS; January 1, 2004 to December 31, 20 1
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SPATIAL ANALYSIS OF HEPATITIS C VIRUS AMONG REPORTED FEMALE CASES 
IN SOUTH CAROLINA: AN ECOLOGICAL STUDY  
4.1 Abstract 
Chronic Hepatitis C virus (HCV) is a continuing global public health threat 
affecting millions worldwide and in 2007 the number of HCV-related deaths exceeded 
the number of HIV-related deaths in the United States. The purpose of this study was to 
investigate the spatial distribution of reported female cases of HCV in South Carolina 
(SC) so as to identify areas with high risk for HCV infection and describe their 
characteristics for targeted public health action. Additionally, we assessed if the number 
of drug abuse treatment admissions, an indicator for drug use, was a potential explanatory 
covariate for HCV risk in these areas. We evaluated aggregated counts of reported HCV-
infected female cases that occurred in SC between 2004 and 2011. Using a Bayesian 
hierarchical spatial model that included potential confounders, a map with smoothed 
standardized morbidity ratio’s (SMR) for HCV diseas was created for each of the 46 
counties in SC. Of the 10, 197 HCV-infected reports received for the study period, 8,511 
(83.5%) reports with geographical information were us d for our spatial analysis. There 
was significant variation in the HCV risk among thecounties in SC. Nine out of the 




counties were mainly located along the coastal, midland and mountain regions of the 
state. Even though six of these high-risk counties w re areas with metropolitan centers, 
the remaining three were federally designated rural counties that had low per capita 
incomes and a large proportion of its residents living in poverty. We found no link 
between the number of drug abuse treatment admissions and HCV risk among these 
counties. Our results establish that there are areas in SC where the observed count for 
HCV infections is higher than expected. Targeted public health action is needed to help 
reduce the risk of the disease in these areas, especially in those rural counties. Future 
research should consider other unmeasured factors so a to better understand the 
underlying cause for high HCV risk in these counties. 
4.2 Introduction 
Chronic Hepatitis C virus (HCV) is the most common blood-borne infection and 
the leading indication for liver transplantation in the United States (US) 109, 110. There are 
at least 3.5 million US residents who are infected with HCV 83, 84. Of the three types of 
viral hepatitis (hepatitis A, B, and C), HCV accounted for the most deaths and had the 
highest death rate between years 2006 and 2010 61, 111. As of 2007, the number of HCV-
related deaths in the US exceeded the number of HIV-related deaths 5.  
HCV is largely transmitted through percutaneous exposure to infected blood and 
injecting drug use (IDU) is often the principal risk factor for disease transmission. Thus, a 
substantial proportion of ‘newly diagnosed’ HCV infections are confined to individuals 
who have a history of injecting drugs or are current injecting drug users (IDUs) 97. 
National trends reveal an emerging epidemic of HCV infections among young non-urban 




descriptive study that used reported HCV-infected female cases uncovered a similar 
pattern; there was a substantial increase in the number of HCV infections reported for 
white females between the ages of 15 and 25 years afte  comparing 2004 data to 2011 
data 113.  In spite of these findings the spatial epidemiology of these HCV-infected cases 
have not been investigated and it is unknown if these r ported HCV cases occur more in 
rural SC as has been previously reported in other US states 1, 98, 99.  
Disease mapping provides a visual representation of how disease is 
geographically dispersed. Assessing the geographic distribution of disease cases, 
especially those recorded through disease surveillance, has the potential of identifying 
areas of unusual high risk so that public health acion may be taken 114. Such initial work 
can enable better resource allocation and efficient r sk assessment as well as enhance 
policy decision-making 114. Furthermore, disease mapping may generate new causal 
hypothesis that can be used to provide context for futu e analytical studies 115.  
Increasingly in spatial epidemiology, Bayesian small area risk models have been 
consistently used to map disease risks as well assess associations between potential 
explanatory covariates and disease risk estimates. Yet, there is only one US study 116 to 
date that has employed the use of these Bayesian disease mapping techniques to evaluate 
the geographic distribution of HCV cases reported through disease surveillance. 
Using previously reported data 113, we conducted an ecological spatial analysis of 
prevalent HCV females cases in SC from 2004 to 2011 to identify which counties in SC 
exhibit elevated risks for HCV infection and to describe the population characteristics of 




treatment admissions within these counties as a potential explanatory covariate for HCV 
disease risk.  
 
4.3 Methods 
Hepatitis C data 
The SC Division of Acute Disease Epidemiology (DADE) provided the viral 
hepatitis data for this analysis. We included all confirmed or probable female cases of 
HCV with a report date between January 1st, 2004 and December 31st, 2011 along with 
demographic data on the reported age, race, zip code an  county of residence. The case 
definitions used here and database from which these ca s were extracted from have been 
described elsewhere 113. Approval was received from SC Department of Health nd 
Environmental Control (SCDHEC) and the University of SC Office of Research 
Compliance. 
Drug abuse treatment admission data 
Drug abuse treatment admission is an indicator of illicit drug use several studies 
used it to monitor national trends in drug use and buse have 117-119. Aggregated county 
data on the number of admissions for drug abuse treatment came from the Department of 
Alcohol and other Drug Abuse Services (DOADAS). Publicly funded drug abuse 
treatment facilities in SC are required to report patient information recorded at the time of 
intake to DOADAS. Reported data elements include the patient’s primary or secondary 
substances of abuse, the route of intake, age, gender, race, county of residence, type of 
treatment and prior treatment admissions. DAODAS data covers all admissions rather 




dataset. For the purpose of our analysis, we only considered unique admissions for where 
the primary, secondary or tertiary substance of abuse involves cocaine, 
methamphetamine, opiates, sedatives or stimulant use. Only treatment admissions for SC 
female residents that occurred from 2005 to 2011 were used for our analysis. Data from 
2004 was unavailable and therefore not included in our analysis. We excluded any 
treatment admissions for patients whose primary or secondary substance abuse problem 
was listed as alcohol, marijuana or hashish.   
Geographic location and population data 
Our geographical unit of analysis was the county and we considered all 46 
counties within the state for our spatial analysis. Data describing the population and 
socio-economic conditions within each county were obtained from the US Census 
Bureau, USA counties data file download 120 and included as potential confounders of 
HCV disease risk in our Bayesian hierarchical model. After review of literature, our list 
of potential confounders included the proportion of White female residents (race) in 
2007, proportion of persons aged ≥ 24 with a bachelor’s degree or higher (education) 
between 2005 and 2009, percentage of foreign born residents from 2005-2009, as an 
indicator of resident immigrant population and percentage of people of all ages living in 
poverty in 2007.  Population counts of females residing in each county were total average 
female population count from 2004 to 2011, and this wa  also obtained from US Census 
Bureau. These data were used to calculate indirectly standardized morbidity ratios (SMR) 
described below. The geographic boundary file used in this was study was downloaded 






This study is ecological and investigates the spatial distribution of HCV infection 
within the state of SC. We performed our spatial anlysis of reported HCV-infected cases 
in three steps: First, we estimated the expected number of HCV cases in each county. 
Expected counts are based on the size of the population iving in each county.  Secondly, 
we calculated the standardized morbidity ratio (SMR) for HCV cases in each county, by 
dividing the observed counts of HCV-infected cases by the expected number. SMR 
values above one represent areas with elevated levels of disease risk whereas values 
below one indicate an area of reduced disease risk. Lastly, using a full Bayesian 
approach, a geographically weighted Poisson model with a random spatial effect term 
was applied to ‘smoothen’ the raw SMRs before mapping 121. This last step was repeated 
for an unadjusted model, a model that only included our main covariate of interest and a 
final model that included all the potential confounders and our main covariate of interest. 
Bayesian spatial smoothing of SMRs for small area disease mapping reduces 
random fluctuation of rates from unstable SMRs due to small counts and small 
population sizes 114, 122-124.  Since HCV counts are often small and rare, case ounts were 
modeled with a Poisson distribution. We used a Bayesi n hierarchical model with a log-
link, proposed by Besag, York and Molli (BYM model) in 1991 125, to fit the raw 
SMR’s with our covariate of interest (total number of drug treatments) and potential 
confounders. The BYM model is a hierarchical model that uses a conditional auto-
regressive distribution and incorporates the effect of neighboring areas under study 126 124, 
125. Put differently, the BYM model shrinks unstable risks toward the local mean risk by 




covariates by subtracting the mean and then dividing the result by its standard error.  We 
implemented the BYM model in WinBUGS 128 using Monte Carlo Markov Chain 
(MCMC) simulation, in which samples are generated from a posterior distribution given 
observed values. We generated 200,000 iterations with the first 20,000 discarded as 
“burn-in” values. The estimated mean relative risks and parameters from these samples 
along with their corresponding 95% credible intervals were computed and mapped. To 
ensure that our model converged the time series plot r duced in WinBUGS were 
visually checked and assessed. Significant high-risk areas were determined from 95% 
credible intervals obtained with WinBUGS using our full Bayes BYM model. All of our 
spatial analysis and graphing were completed with R statistical program 96 version 2.12.  
4.4 Results 
Our initial dataset consisted of 10,197 reports of chronic HCV-infected female 
cases that were reported to DADE between 2004 and 2011. Of these, 1,686 (16.5%) cases 
were missing geographical location information and were excluded from our analysis. 
Our final data used for the spatial analysis consisted of 8,511 reports. Eighty-eight 
percent (n = 7,473) met the clinical definition fora confirmed case and 40% were 
assessed by either a RIBA or RNA test. The mean age of all the cases was 47.7 years. 
None of the 46 counties had zero observed counts of HCV infection and counties with the 
highest concentration of HCV reports matched up to major metropolitan areas in SC 
(Figure 4.1). 
The posterior means and Deviance information criterion (DIC) values from our 
Bayesian hierarchical model are summarized in Table 4.1. From this table, we selected 




model contained our standardized main covariate variable of interest (total number of 
drug treatment admissions) and potential confounders (race, education, proportion of 
foreign-born residents and poverty). From this analysis, no significant associations 
between total number of drug treatment admissions and HCV infection risk were 
detected.  
Unsmoothed raw SMR’s for HCV infection ranged from 0.11 to 3.26.  However, 
because these raw estimates can be very imprecise due to areas with small populations 
and are affected by possible spatial correlation betwe n disease risks in nearby areas, we 
used our Bayesian model described above to produce smoothed estimates of disease risk. 
Several counties with significant risks for HCV infection emerged (Figure 4.2) from this 
analysis. Our smoothed relative risks ranged from 0.26 to 2.82 and high-risk areas for 
HCV infection were observed in the coastal, midlands and Piedmont (mountain) regions 
of the state. Based on our computed credible intervals from the BYM model, nine out of 
the fourteen counties with an SMR >1, were statistically significant. Specifically, the 
counties of Charleston, Darlington, Florence, Georgtown, Greenville, Horry, Oconee, 
McCormick and Richland showed a significant high risk for HCV infection. The socio-
economic characteristics of these areas are summarized in Table 4.2.  Compared to the 
per capita income of $33,388 from 2012 129 for the entire state, four of the nine counties 
had lower per capita incomes. Three counties (McCormick, Georgetown, Oconee) were 
federally designated rural counties whereas the remaining counties were counties with 
metropolitan centers. Of note, McCormick county exhibited the highest risk for HCV 




the largest percentage of people of all ages living in poverty and the lowest percentage of 
persons, 24 or older, with at least a college degree.   
4.5 Discussion 
We investigated the spatial epidemiology of HCV infections in South Carolina 
(SC) as reported to disease surveillance between 2004 and 2011 using Bayesian 
smoothing techniques.  The results revealed that there is substantial variation in HCV 
infection risk among the counties in SC and several of these counties were identified as 
high-risk areas. These high-risk counties were a mixture of metropolitan and rural areas 
distributed across the state. We did not find a significant relationship between number of 
drug abuse treatment admissions reported in these counties and the HCV disease risk. 
Additionally, we detected no relationship between HCV risk and confounding covariates 
for which we adjusted in the BYM model. 
Even though it has been well established that injecti g drug use (IDU) is a leading 
risk factor for HCV infection in developed countries, the number of drug abuse treatment 
admissions in our Bayesian model did not explain the observed spatial variations in HCV 
infections in SC. One explanation to this finding is that our aggregated counts of drug 
abuse treatment admissions may not accurately reflect th  extent of illicit drug use within 
counties in SC. Since only publicly funded treatment centers report their data to 
DOADAS, data from privately funded treatment centers are not included in these counts. 
Furthermore, the treatment population represented i the DOADAS data set may not be 
representative of all patients undergoing drug abuse treatment in SC. Lastly we could not 




Yet, the fact that there was little change in the SMR’s after adjusting for potential 
confounders (race, percent foreign born, education and poverty) and applying smoothing, 
is an important observation in itself.  This implies that there are other unobserved factors 
that might be account for the high HCV prevalence in these areas and will require further 
investigation. Up until recently, HCV infection related to IDU risk behavior was 
understood to occur more in metropolitan centers as it is where drug trade is high and 
readily available. However this notion is quickly changing. Three (33%), out of the nine 
high-risk counties we identified were federal designated rural counties which, 
corresponds to recent reports of an emerging HCV epidemic in rural and suburban 
communities within the US 1, 98, 112. It is believed that this emerging problem may be 
related to the national opioid epidemic seen largely in young injectors in nonurban areas 
130, 131.  
The interpretation of our findings must also consider some weaknesses. First, 
since small area analysis are ecological approaches, results obtained from this aggregated 
levels of observation cannot be used to make assumptions regarding individual risks as 
the result may not hold true at individual levels. Secondly, the geographic resolution at 
which this study was carried out may have impacted our results, as aggregating data to 
different areal arrangements (e.g. census or neighborhood tracts) may lead to different 
results which may affect the interpretation of our findings 127.  Another limitation to 
consider is the fact that about 16% of all the HCV cases reported for study period were 
excluded because of missing location data. These exclusions may have impacted the 
observed HCV prevalence. Lastly, the HCV surveillance cases used here are a mixture of 




showing signs of chronic liver disease. Therefore, it is likely that the data to some extent, 
may reflect screening practices and initiatives rather han true prevalence or incidence of 
HCV infection in various regions 116.  
Taken these limitations into account, we were able to identify counties in SC with 
significant HCV infection risks that warrant further investigations. The characteristics of 
these significant high-risk areas described here should also motivate more targeted 
prevention efforts to be undertaken within the state of South Carolina. Even though we 
were unable provide a reasonable explanation as to why McCormick county exhibited an 
unusually high SMR, this finding warrants further investigation by public health officials 




Table 4.1- Final Besag,York and Molli  (BYM) model for reported female cases of hepatitis 
C virus (HCV) infection, South Carolina, 2004-2011, posterior means and 95% credible interval 
Parameter  Posterior mean 95 % Credible Interval 
Total number of Drug abuse 
treatment admissions 1.01 0.97-1.05 
Proportion White 1.00 0.97-1.04 
Proportion aged ≥ 25 years 
with at least a college degree 
or higher  1.02 0.99-1.06 
Proportion of foreign 
residents 0.97 0.95-1.00 
Proportion of all ages living 
below poverty  0.98 0.95-1.02 
Model Included covariate DIC 
1. Unadjusted None 389.692 
2. Adjusted for Drug  Drug 389.304 















































SC 8,522 2,063,083 33,388 14.30 68.7 23.5 4.4 68,010 - 
McCormick 57 4,659 27,509 19.6 50.7 14.9 1.6 88 2.8 
Florence 383 66,662 34,450 17.8 57.5 20.6 2.4 1,913 1.44 
Richland 932 165,940 36,347 12.7 50 36.6 5.1 4,455 1.34 
Darlington 177 35,513 29,355 18.7 56.9 17.1 1.6 1,65  1.31 
Georgetown 152 29,097 38,403 17.7 65.1 22 3.1 682 1.28 
Oconee 169 33,661 31,964 13.9 90.4 21 3.3 1,420 1.24 
Charleston 787 160,182 41,656 15.2 65.5 36.7 5 5,273 1.19 
Horry 561 100,095 29,148 14 83 21 6.2 2,757 1.17 
Greenville 950 194,834 37689 12.2 78 29.1 7.8 7, 001 1.15 
SMR= standardized morbidity ratio; HCV=hepatitis C virus; SC=South Carolina. 
b Proportion of people with age ≥ 25 with a college degree or more 
a Proportion of people of all ages living in poverty in 2007. 
 

















Figure 4.2 Standardized morbidity ratios 
female cases of hepatitis C viral infections in South Carolina, 2004
 













PREGNANCY OUTCOMES IN WOMEN INFECTED WITH HEPATITIS B OR C VIRUS 
5.1 Abstract 
The objective of this study was to estimate the association between maternal 
hepatitis B or C (HBV, HCV) infection status during pregnancy and preterm birth, small 
for gestational age (SGA), low birth weight (LBW) and neonatal intensive care unit 
(NICU) admission. We utilized data from a cohort of singleton pregnancies from women, 
aged 15-49, whose births were recorded in the South Carolina birth registry between 
2004 and 2011. Restricting our analysis to women who contributed more than one 
pregnancy over the study period, we used logistic regression to analyze pregnancy 
outcomes after a subsequent pregnancy after considering infection status in a prior 
pregnancy.  A total of 438,208 singleton pregnancies in women aged 15-49 years were 
recorded in the SC birth registry over the 8-year study period. Of these, 211,457 (48.3 %) 
pregnancies were from women who contributed two or m e consecutive pregnancies 
prospectively and 95,291 (21.7%) pregnancies were subsequent pregnancies that were 
used for the analysis. Among pregnancies that were studied, 276 (0.29%) were HCV- 
infected and 236 (0.25%) were HBV-infected.  After adjusting for known confounders 
babies born to HCV-infected mothers whose status changed from a non-diseased state in 
their previous pregnancy, to a diseased status in the r subsequent pregnancy had higher 




No increase in odds was identified for HBV mothers. Our results supports an association 
between LBW and HCV infection, specifically for mothers who transitioned from a non-
infected status state in their previous pregnancy, to an infected status during their 
subsequent pregnancy in our study.   
5.2 Introduction 
Approximately one third of the world’s population have been infected with 
Hepatitis B virus (HBV) and between 130-170 million, 2-3% of the world’s population, 
are chronically infected with hepatitis C virus (HCV) 82. Together, both infections 
constitute a major global health problem as they cause significant liver-related morbidity 
and mortality among those infected 60, 80. In low endemic regions, such as the United 
States (US), HBV and HCV affect a considerable propo tion of women. Based on data 
from the National Health and Nutrition Examination Surveys (NHANES), chronic HBV 
infection affects about 0.19% of women whereas approximately 1.1% are chronically 
infected with HCV 12, 84.  
There have been varied reports on the prevalence of HCV and HBV infection in 
pregnant women and in women of childbearing age. Within the US, around 0.06 to 1% of 
pregnant women are said to be infected with HCV 28, 44, 48, 50, 132 whereas 0.09% to 5.7 % 
of antenatal women are infected with HBV26, 28, 44, 48, 93, 133. Even though these numbers 
appear to be small, they correspond to several thousands of HCV- and HBV-infected 
pregnant women who deliver at risk babies in the US annually. For instance, in one study 
that used birth registry data from 22 US states, it was reported that about 16,608 women 




The literature on how pregnancy outcomes are impacted by these viral infections 
remains inconclusive. Current knowledge linking prete m birth, small for gestational age 
(SGA), low birth weight (LBW) and neonatal intensive care unit (NICU) admission to 
maternal HBV or HCV infection is controversial, as these results have been mixed. While 
some studies have found an increased risk for preterm birth 44, 45, 47, SGA 44, 50, LBW 44, 48, 
50 and neonatal intensive care unit (NICU) admission50 50in HCV- and HBV-positive 
women, other studies 28, 44, 50, 51, 57 have found differently. For example, three studies 45, 55, 
134 that examined preterm births found no increased risk among mothers who tested 
positive to hepatitis B surface antigen (HBsAg) whereas two other studies 45, 47 reported 
an increased risk for preterm births among HBsAg positive women. With the exception 
of a few papers 28, 44, 50, most studies used small sample sizes, which limited their 
generalizability. Even more importantly, ICD-9 codes were used to ascertain disease 
exposure status and/or other potential confounders and it is likely biases from residual 
confounding and inaccurate exposure assessment were introduced into these studies.  
Hence, more information from large, population studies that overcome some these 
limitations are needed to better understand how being HCV- or HBV-positive during 
pregnancy may impact birth outcomes. Additionally, the conventional statistical 
approaches used in previous studies 44, 50have ignored correlations resulting from the 
clustering of multiple pregnancies from the same mother. Also, the fact that infected 
cases may belong to groups of “recently diagnosed” or ‘chronic carrier’ cases have been 
overlooked.  Assuming that there is a carryover effect rom a prior infected pregnancy or 
ongoing treatment, the risk of an adverse pregnancy outcome may be different for newly 




  In the present study, we sought to estimate the association between maternal 
HBV or HCV status with preterm birth, SGA, LBW and NICU admission among a 
retrospective cohort of antenatal women from the South Carolina (SC) birth registry data. 
Our approach was to assess if there was a differenc in the risk (which is equal to the 
odds given that these outcomes are rare) for an adverse pregnancy outcome for “recently 
diagnosed” and  ‘chronic carrier’ cases of maternal HCV or HBV infection compared to 
subsequent non-infected pregnancies. 
5.3 Methods 
This secondary data analysis utilized data from the SC birth registry, where data 
pertaining to all live births are recorded, the South Carolina (SC) Health Electronic 
Surveillance System (CHESS), a database that contains surveilled female cases (probable 
and confirmed) infected with HCV or HBV, and the Department of Alcohol and Other 
Drug Abuse Services (DOADAS), which contains patient l vel information on treatment 
admissions for substance abuse. Detailed information on the methods used to link birth 
registry data to CHESS is reported elsewhere 93, 113 Furthermore, an assessment of the 
concordance between these two data sources for matenal HBsAg infection status showed 
that the agreement was moderate and that our sensitivity for finding HBsAg positive 
cases in the birth registry was enhanced through the linkage 93. 
Approval for this study came from the Institutional Review Boards for the SC 
DHEC, the University of SC Office of Research Compliance and the SC Budget and 
Control Board, Office of Research and Statistics (ORS) Data Oversight Committee. From 
the birth registry data, we selected all singleton pregnancies from women, aged 15-49, 




additionally linked the birth registry/CHESS file to substance abuse treatment admissions 
data from DAODAS.  All publicly funded drug abuse tr atment facilities in SC are 
required to report patient information recorded at the time of intake to DOADAS. 
Reported data elements include the patient’s primary or secondary substances of abuse, 
the route of intake, age, gender, race, county of residence, type of treatment and prior 
treatment admissions. Since information on alcohol use that is recorded on the birth 
certificate is known to be unreliable 79, linkage to DAODAS enabled us to obtain 
additional information on the alcohol and drug abuse/ e history of subjects in the birth 
registry. We only used treatment admissions data for SC female residents that occurred 
from 2005 to 2011, as data from 2004 was unavailable for linkage.  
Exposure definition 
Maternal HCV or HBV status was ascertained from the linked CHESS/birth 
registry data. The case definitions used to describe probable or confirmed cases of HCV 
and HBV from CHESS have been described elsewhere in d tail 93, 113.  Our exposed 
cohort was made of singleton pregnancies where the mother was known to be either HBV 
or HCV positive prior to or during that observed pregnancy. We considered a case 
positive if it was reported to CHESS prior to or duing the year of childbirth. 
Additionally, we also included positive cases from the birth data that were not reported to 
CHESS as being HCV or HBV positive. Pregnancies that occurred before a notification 
was made in CHESS or were not positive on the birth certificate were considered 
negative and these pregnancies made up our non-infected cohort. Any pregnancies that 





Pregnancy outcomes  
We had four main outcomes of interest in this study and these were preterm birth, 
low birth weight (LBW), small for gestational age (SGA) and neonatal intensive care unit 
(NICU) admission. A recent validation of the SC birth certificate data showed that 
obstetric estimate of gestational age, birth weight in grams and NICU admission were 
among the variables with excellent agreement and sesitivity 135. Obstetric estimation of 
gestational age has also been previously validated in the US birth registry data 136. 
Preterm birth was ascertained from obstetric estimate of gestational age in weeks and 
infants were considered preterm if they were born before 37 weeks. Any births with a 
gestational age of ≤ 20 weeks were excluded from this study, as these births are often not 
viable. We defined LBW as < 2,500 grams at the time of birth. SGA, a measure of fetal 
growth restriction, was assessed as birth weight below the 10th percentile for gestational 
age according to fetal sex on standardized weight charts developed by Alexander et al. 
137. 
Maternal characteristics 
Maternal covariates of interest were abstracted from the linked birth 
registry/DAODAS file and these were included as potential confounders in our analysis. 
We categorized our potential confounders into two main groups: socio-demographic 
confounders and risk factor confounders.  These potntial confounders were selected 
based on a review of the literature, biological plausibility and on whether or not they 
were statistically significant in our univariate analysis.  Socio-demographic confounders 
included maternal age (<20 vs. 20-29 vs. ≥ 30 years), race/ethnicity (non-Hispanic white 




vs. beyond high school), Women and Infant Care (WIC) program participation (yes vs. 
no), payer source (Medicaid vs. private insurance vs. self pay vs. other) and adequacy of 
prenatal care (inadequate vs. intermediate vs. adequat  vs. adequate plus vs. unknown). 
Adequacy of prenatal care was determined by using the revised graduated index proposed 
by Kotelchuck, which has been found to describe the lev l of prenatal care utilization 
among high-risk groups quite well 138, 139.  
All of the risk factor related variables were dichotomized as yes vs. no. Risk 
factor confounders consisted of maternal tobacco use d ring pregnancy, presence of a 
sexually transmitted infection (STI), previous adverse outcome, other morbidities and 
history of alcohol or drug abuse. The presence of an STI was assessed as presence of any 
of the following infections during pregnancy; syphilis, gonorrhea, chlamydia and genital 
herpes. For previous adverse outcome, which also reflect d the reproductive history of 
each case, we created a composite variable to represent a previous preterm birth or 
previous poor pregnancy outcome to include a perinatal death, small-for-gestational age 
and intra uterine growth restriction. By including prior adverse birth outcomes in the 
model, we focus on the risk that is related to a chnge of the infection status. Other 
pregnancy morbidities were considered present if any of the following conditions were 
checked on the birth certificate: pre-pregnancy hypertension, pre-pregnancy 
hypertension, gestational hypertension, fertility trea ment, previous cesarean, gestational 
diabetes and vaginal bleeding. Women were classified as having a history of drug or 
alcohol abuse if they were found in the DAODAS datab se and reported alcohol, cocaine, 
methamphetamine, opiates, sedatives or stimulant use as either their primary, secondary 




primary route of drug of use. Lastly, we considered the parity of the pregnancies and 
interval between their prior and subsequent pregnancy s continuous variables in our 
analysis. 
Statistical analysis 
Our analysis was restricted to a subset of women who had two or more 
subsequent pregnancies captured in our dataset over he ight-year study period. From 
this group, we assessed pregnancy the incidence of preterm birth, LBW, SGA and NICU 
admission as it pertained to maternal HCV and HBV infection (Figure 5.1).  We 
categorized our exposure group into three levels based on their exposure status at the time 
of their initial and subsequent pregnancy. Our reference group consisted of those 
pregnancies that had no disease in their initial and subsequent pregnancy (non-diseased). 
Our “recently diagnosed” group included those mothers who were without disease at the 
time of their initial pregnancy and then positive at the time of their subsequent 
pregnancy. Lastly, our ‘chronic carriers’ disease group, was defined as all those who had 
HBV or HCV disease in both their initial and subsequ nt pregnancy.  
We used the Pearson Chi-square (χ2) statistic to compare socio-demographic and 
risk factor variables between non-infected and infected pregnancies. Descriptive statistics 
were presented as number (percentage) for categorical variables and in mean (range) for 
continuous variables such as parity and interval betwe n pregnancies. As we were only 
assessed outcomes for one time point (t=1), only one pregnancy was contributed by each 
woman to the dataset, thus, we had no issue with clustering from multiple pregnancies 




Multivariable logistic regression model using PROC GENMOD in SAS, was used 
to model the effect of ‘recently diagnosed’ and ‘chronic carrier’ infections of HCV and 
HBV disease on preterm birth, LBW, SGA and NICU admission. We included our main 
exposure of interest as categorical variable with three levels (non-diseased vs. ‘recently 
diagnosed’ vs. ‘chronic carrier’) into our regression model with non-diseased group 
serving as our baseline reference group. In order to see how our parameter estimates 
changed, with the addition of confounding variables to the model, we used a forward 
stepwise modeling approach that entered a block of variables at a time. Consequently, 
three models were fitted for each outcome, per disease (HCV or HBV). Since past 
reproductive history is strongly associated with birth outcomes 140 our crude model 
included our main covariate adjusted for previous adverse pregnancy outcome, parity and 
interval between initial and subsequent pregnancy.  In this first model, the unadjusted 
odds ratios (ORs) were calculated for the associatin between each outcome and our 
main covariate variable. Next, the ORs in the second model were additionally adjusted 
for socio-demographic confounding variables. Finally, the ORs in our fully adjusted 
model included risk factor variables and all the variables contained in second model. All 
statistical tests were performed using SAS (version 9.3, SAS institute, Inc.).  
5.4 Results 
There were 438,208 singleton pregnancies in women ag d 15-49 years recorded 
in the SC birth registry over the 8 study years, 2004- 2011. After excluding cases, which 
were co-infected with both HCV and HBV (n=30), 438,178 pregnancies remained.  Of 
these, 211,457 (48.3 %) pregnancies were from women who contributed two or more 




subsequent pregnancy (t=1), we had 95, 291 (21.7%) pregnancies (Figure 5.1). Among 
the pregnancies that were studied, 276 (0.29%) wereHCV-infected and 236 (0.25%) 
were HBV-infected. Removing pregnancies with missing SGA (n=31), LBW (n=7), 
payment source for delivery (n=646), WIC usage (n=6), parity (n=45), race (n= 195), 
maternal education (n=321) and tobacco use during pe nancy (n=66) left a total of at 
least 93, 814 pregnancies for our multivariate analysis.  
Table 5.1 summarizes the differences between HCV-, HBV- and non-infected 
pregnancies in terms of selected socio-demographic and risk factor characteristics at the 
time of a subsequent pregnancy. Compared to mothers with non-infected pregnancies, 
HCV-infected mothers were young adults; and were more likely to be of Black non-
Hispanic race, participate in WIC, use Medicaid payment for delivery, smoke during 
pregnancy and to receive a lower level of prenatal care. They were also more likely to 
have a history of alcohol and drug abuse.  HBV-infected mothers were also young adults. 
They were more likely to be of Hispanic race, have t least a high school education, 
participate in WIC, use Medicaid as a source of payment for delivery and have tested 
positive for an STI.  
When we compared the frequencies of adverse pregnancy outcomes between non-
infected pregnancies and infected pregnancies (Table 5.2), those that were HCV-infected 
were more likely than non-infected pregnancies to have a LBW, small for gestational age 
and an admission to the NICU unit. These significant differences were not observed for 
HBV infections.   
 Crude and adjusted OR’s for the association between pr term birth, NICU 




5.4. Our analysis revealed a significant relationship between delivering a baby with low 
birth weight and maternal HCV infection among the ‘recently diagnosed’ group. After 
adjusting for potential confounders, HCV-infected cases who went from a non-diseased 
state in their previous pregnancy, to a diseased status in their subsequent pregnancy had 
higher odds of LBW (OR=2.07, 95% CI 1.28- 3.37) after being compared to non-infected 
cases. After adjusting for risk factors, the association for preterm birth and SGA related 
to HCV-infection in the ‘recently diagnosed’ group became marginally significant 
respectively (OR= 1.85, 95% CI: 0.95-3.6, p-value=0.06; and OR=1.85; 95% CI: 0.95-
3.60, p-value =0.07). We found no significant associations for HCV infection and NICU 
admission. Likewise, when we examined the models for HBV-infected cases, we found 
that being HBV-infected, be it a ‘recently diagnosed’ or a ‘chronic carrier’ case, did not 
confer an additional risk for LBW, SGA, preterm birth and NICU admission.   
5.5 Discussion 
Our analysis of data from the SC birth registry revealed that being a ‘recently 
diagnosed’ HCV-infected case was independently associated with LBW but not preterm 
birth, SGA and NICU admission. We also found no signif cant associations between 
HBV infection and these outcomes.  
As I have already noted, the few studies of HCV infection and adverse birth 
outcomes have provided controversial results. Two large population-based US studies 
found that HCV-infected mothers were at an increased risk of delivering LBW and SGA 
babies and babies who were admitted into NICU 44, 50. Conversely, findings from Haider 
et al. 56, Jaffery et al.57 and Hillemanns et al. 52 showed that being HCV-infected during 




in these latter studies is that they were conducted in antenatal clinics that attended to 
‘high-risk’ prenatal clients.  Therefore, selection bias and use of small sample sizes could 
have affected their results. Our analysis drew from a large population-based cohort of 
pregnant women and assessed the change in infection status as exposure. While our 
approach to analysis was different from that used in previous studies, our overall finding 
with HCV infection is consistent with the findings of Connell et al. 44 and Pergam et al. 
50, who both used birth registry data.  
We were surprised not to detect a difference in risk for those ‘chronic carrier’ 
patients, that is, those that had a positive HCV or HBV status in their initial and 
subsequent pregnancies. Yet, no such significant associations were revealed in our 
analysis. One likely reason is that, we did not have  sufficient number of events in this 
group to be able to detect a significant effect. Another plausible explanation could be that 
after the discovery of their infection status, patien s may have undergone antiviral therapy 
to control and stabilize their viral disease before conceiving again. Some studies that 
demonstrated improved outcomes in infected individuals who have undergone interferon 
therapy and are without persistent viremia 141, 142. Therefore, if these patients had low 
viremia in their subsequent pregnancies it is unlikely the disease had any impact on their 
pregnancy outcome. Unfortunately, since our data did not include any information about 
HCV or HBV viremia or viral load during pregnancy, we had no way of confirming this 
speculation.   
 Earlier studies on HBV infection and birth outcomes have found significant risks 
for preterm birth 45, 47 and SGA 44 whereas other studies 44, 45, 55, 134 that looked at preterm 




HBsAg. This study demonstrated a null effect for prete m birth, SGA, LBW, NICU 
admission and HBV infection. Though our results differ rom the earlier non-US studies 
that have come from small centers, our finding for HBV is similar to the only other US 
study that used birth registry data. With the exception of SGA, Connell et al. found no 
significant risks associated with being HBV infected during pregnancy. Even though both 
virus primarily infect hepatic cells, they are virologically distinct and display numerous 
clinical differences 143. For example, most adults infected HBV are able to clear their 
infection spontaneously, resulting in lifelong protective immunity whereas 60-80% of 
adults with HCV fail to control the infection and develop chronic disease 143. A plausible 
explanation to this observation may lie in the divergent immune responses produced by 
HCV and HBV. Studies have already linked circulating pro-inflammatory cytokines from 
maternal innate and adaptive immune responses to adverse pregnancy outcomes 144-146. 
Accumulating evidence suggests that there is a lack of interferon response during HBV 
acute infection resulting from the inactivation of various pathways that will normally 
induce interferon and cytokine production147. In other words, HBV ‘evades’ the innate 
immune response by not inducing it to act whereas HCV induces a strong innate and 
adaptive immune response 148, 149 which leads to interferon and cytokine production 
during the initial stage of infection. From this knowledge, it can be gathered that the 
‘stealth’ of HBV may perhaps be the reason why no effect was seen for HBV infection. 
 Our study has limitations that should be acknowledged.  First, our approach to 
this analysis only included outcomes after the subsequent pregnancies that were observed 
prospectively. These pregnancies may not necessarily h ve be the second pregnancy of 




observation window. We acknowledge the fact that our use of the term ‘‘recently 
diagnosed’’ especially for HCV-infected cases does not truly reflect ‘new cases’ of 
infections. Rather, these are past or present infect ons that went undiagnosed for years. 
The fact that our infected pool of cases was largely made up of chronic cases reported 
surveillance underscores this point. In our data se, 49% and 42% of  “recently 
diagnosed” HBV and HCV cases had their diagnosed within 2 years after an initial 
uninfected pregnancy. Among these “recently diagnosed” pregnancies, the frequency of 
preterm birth and LBW were consistently higher for HCV infected cases compared to 
non-infected cases whereas the frequency of SGA was higher among HBV infected cases 
compared to non-infected cases.  In addition, because there is no universal screening for 
HCV, the HCV-positive cases in our data were most likely identified through provider 
initiated risk-based screening. Consequently, the HCV cases here are a mixture of those 
who exhibit high risk factors and those experiencing symptoms of early liver disease. 
Lastly, another limitation to consider is the fact that our data contained no information on 
hepatitis viremia (viral load) or treatment status. Therefore, we were not able to assess 
these variables in our study.  We also had no information on the HIV/AIDS status of 
these mothers thus we were unable to adjust for the effect of this disease in our analysis. 
In spite of these limitations, there are several strengths to this study. Our approach 
to analysis used here enabled us to assess if the rsks for ‘newly diagnosed’ and ‘chronic 
carrier’ cases of disease were different.  Also, by linking birth data to surveillance data, 
we were able to improve our sensitivity for case finding in the birth data, thus the 
potential for misclassification of maternal disease status was greatly reduced. Further 




alcohol use. These are variables that would otherwis  not be available in the birth 
certificate data. Lastly, our sample of subsequent pregnancies was comparable to all the 
singleton births (see Appendix D) that occurred in SC over the study period. If we 
consider the state of South Carolina as a sampling unit of Southern US, our data may well 
be representative of the demographic composition of women in residing in this region of 
the US. Therefore our results are generalizable to populations in the south with similar 
demographics. .  
In summary, our data supports an association between LBW and HCV infection, 
specifically for mothers who were ‘recently diagnosed’ in our study.  These findings have 
some implications for HCV-positive women entering ito prenatal care. LBW is an 
important risk factor for infant mortality 150, 151 and from a practice point of view, this 
information is useful for providers to advise infected expectant mothers on the potential 
risk to their baby. Although universal screening for HCV infection during pregnancy is 
not currently recommended in the US, given our findings, additional steps, such as 
improving nutrition and receiving adequate prenatal care can be taken to help reduce the 
effect of this disease on pregnancy outcome. The current interferon therapy for HCV 
infection is not indicated for pregnant women and there is no vaccine to prevent perinatal 
HCV infection, however that may soon change. When tat time arrives, linkage to care 
during pregnancy may help reduce the risk of this disease on low birth weight. But until 
such a time, future studies should consider investigating how a patient’s viremia affects 
pregnancy outcomes. Finally, more population-based stu ies with more power are needed 





Table 5.1- Characteristics of HCV-infected and HBV-infected pregnancies in South Carolina, 
2004 -2011 
 
Non-infected HCV+ HBVa + 
number (%) number (%) number (%) 
  n=(94, 870)  (n= 275) P-valueb (n=235) P-valueb 
Socio-demographic 
variables 
Age in years, median 
(range) 26 (15 - 49) 27 (17 - 41) 0.006c 27 (17-43) 0.001c 
< 20 years 6556 ( 7) 14 ( 5) 0.24 11 ( 5) 0.047 
20-29 years 58467 (62) 164 (60) 134 (57) 
≥ 30 years 29757 (31) 97 (35) 90 (38) 
Race/ethnicity <.0001  <.0001 
non-Hispanic White 8669 ( 9) 12 ( 4) 20 ( 9) 
non-Hispanic Black 52306 (55) 187 (68) 60 (26) 
Hispanic 32064 (34) 69 (25) 103 (44) 
Other 1546 ( 2) 7 ( 3) 51 (22) 
Maternal education 0.0013  0.0063 
< High school  21938 (23) 77 (28)  66 (28)  
High school 24965 (26) 90 (33) 77 (33) 
Beyond high school 47558 (50) 106 (39) 91 (39) 
Did mother use WIC 0.029  0.308 
No 44516 (47) 105 (38) 96 (41) 
Yes 48624 (51) 163 (59) 134 (57) 
Unknown 1634 ( 2) 7 ( 3) 5 ( 2) 
Payment source for 
delivery <.0001  
0.05 
Medicaid 49508 (52) 182 (66)  141 (60)  
Private Insurance 35296 (37) 71 (26) 66 (28) 
Self-pay 5947 ( 6) 10 ( 4) 16 ( 7) 
Other 3385 ( 4) 10 ( 4) 9 ( 4) 
APCU indexe   <.0001  0.06 
Inadequate 20309 (21) 92 (33)  67 (29)  
Intermediate 6635 ( 7) 25 ( 9)  19 ( 8)  
Adequate 27826 (29) 64 (23)  65 (28)  
Adequate plus 39464 (42) 93 (34)  82 (35)  




Table 5.1- Characteristics of HCV-infected and HBV-infected pregnancies in South Carolina, 
2004 -2011 (cont’d.) 
 
 Non-infected HCV+  HBVa +  
 number (%) number (%)  number (%)  
 n=(94, 870) (n= 275) P-valueb (n=235) P-valueb 
Risk factor variables 
Maternal smoking during 
pregnancy   <.0001  0.106 
No 82282 (87) 150 (55)  206 (88)  
Yes 12432 (13) 125 (45)  28 (12)  
Maternal STI during 
pregnancyd   0.27  0.016 
No 88094 (93) 251 (91)  209 (89)  
Yes 6686 ( 7) 24 ( 9)  26 (11)  
Previous adverse 
outcome   0.033  0.688 
No 84739 (89) 235 (85)  212 (90)  
Yes 10041 (11) 40 (15)  23 ( 10)  
Risk factors present in 
pregnancy   0.338  0.39 
No 64590 (68) 180 (65)  154 (66)  
Yes 30190 (32) 95 (35)  81 (34)  
History of alcohol abusef   <.0001  <.0001 
Yes 93125 (98) 237 (86)  223 (95)  
No 1655 ( 2) 38 (14)  12 ( 5)  
History of drug usef   <.0001  0.03 
No 92383 (97) 196 (71)  224 (95)  
Yes 2397 ( 3) 79 (29)  11 ( 5)  
Primary route of drug use <.0001 
Injection or 
intramuscular 107 ( 4) 29 (35)  - 
Other 2290 (96) 51 (65) 11 (100) 
Interval between 
pregnancies, median 
(range), years 2 (<1-7) 3 (<1-7)  2 (<1-7)  
Parity, median (range) 1 (1-22) 2 (1-13)  1 (1-8)  
CHESS=South Carolina Health Electronic Surveillance System; BC = birth certificate (registry) data; HBV= 
hepatitis B virus; HCV=hepatitis C virus, STI= sexually transmitted infections; WIC=women, infant and 
children nutrition program, APCU= adequacy of prenatal care utilization. 
a These include 37 pregnancies confirmed in CHESS as acute HBV cases. 
b Pearson Chi-square test 
cKruskall Wallis test  
dSTI infections include presence of either chlamydia, gonorrhea, syphilis or genital herpes infection fr that 
pregnancy 
e Adequacy of prenatal care utilization index as defined by Kotelchuck (1994) 
fData from Department of Drug, Alcohol and Other Drugs. Indicates if patient has received treatment 




Table 5.2 - Frequency of adverse birth outcomes at the ime of a subsequent pregnancy by exposure to viral hepatitis: South Carolina, 2004-
2011. 
 
Adverse birth outcome 
Non-infected 
(N = 94, 870) 
HCV + 
(N = 275) P valuea 
 HBVb + 
(N =235) P valuec 
Preterm birth       
No  85567 (90) 238 (87) 0.037  211 (90) 0.79 
Yes  9213 ( 10) 37 (13)   24 (10)  
Low birth weight, grams       
No  87933 (93) 240 (87) 0.002  217 (92) 0.95 
Yes  6840 ( 7) 35 (13)   18 ( 8)  
Small for gestational age       
No  86009 (91) 235 (85) 0.0093  208 (89) 0.46 
Yes  8740 ( 9) 40 (15)   27 (11)  
Newborn Admission to 




No  90325 (95) 256 (93) 0.08  217 (92) 0.03 
Yes  4455 ( 5) 19 ( 7)   18 ( 8)  
NICU= Neonatal intensive care unit. CHESS= South Carolina Health Electronic Surveillance System; BC = Birth certificate (registry) 
data; HCV=hepatitis C virus; BC = Birth certificate (r gistry) data; HBV= hepatitis B virus. 
aPearson Chi-square test comparing HCV infected pregnancies to non-infected pregnancies. 
bThese include 37 pregnancies confirmed in CHESS as acute HBV cases. 
cPearson Chi-square test comparing HBV infected pregnancies to non-infected pregnancies 





Table 5.3- Multivariate logistic regression analysis of subsequent pregnancy outcomes after maternal hep titis C viral infection. 
  Model 1a  Model 2b   Model 3c 
OR (95% CI) P-value  OR (95% CI) P-value  OR (95% CI) P-value 
SGA (n=93,829)         
    Non disease- non disease (n=93,557) 1.00  1.00  1.00  
    Newly diagnosed (n=124) 1.95 (1.22-3.13) 0.0051  2.09 (1.29-3.36) 0.0024  1.51 (0.93-2.45) 0.09 
    Chronic carriers (n=148) 1.39 (0.86-2.26) 0.17  1.41 (0.87-2.31) 0.158  1.10 (0.67-1.80) 0.68 
AIC 57704  55362  54892 
Low birth weight (n=93,851)   
    Non disease- non disease  (n= 93,579) 1.00  1.00  1.00 
    Newly diagnosed (n=124) 2.51 (1.58-4.00) 0.0001  2.80 (1.73-4.52) <.0001  2.07 (1.28-3.37) 0.0030 
    Chronic carriers (n=148) 1.14 (0.64-2.03) 0.64  1.17 (0.65-2.10) 0.59  0.84 (0.46-1.53) 0.58 
AIC 47990  45071  449595 
Preterm (n=93,856)   
    Non disease- non disease (n=93, 584) 1.00  1.00  1.00 
    Newly diagnosed (n=124) 1.58 (0.97-2.56) 0.06  1.66 (1.01-2.73) 0.04  1.47 (0.89-2.43) 0.12 
    Chronic carriers (n=148) 1.02 (0.60-1.72) 0.92  1.03 (0.60-1.75) 0.91  0.83 (0.48-1.4) 0.51 
AIC 58866  55402  55060 
NICU Admission (n=93,856)   
    Non disease- non disease (n=93, 584) 1.00  1.00  1.00 
    Newly diagnosed (n=124) 1.6 (0.83-3.06) 0.15  1.63 (0.85-3.15) 0.13  1.39 (0.72-2.69) 0.32 
    Chronic carriers (n=148) 1.23 (0.6-2.4) 0.54  1.20 (0.60-2.38) 0.59  0.98 (0.49-1.95) 0.95 
AIC 35040  34215  33965 
SGA= small for gestational age; NICU=neonatal intensive care unit; CI= confidence interval; AIC=Akaike information criterion. 
aModel 1: Adjusted for parity, previous adverse pregnancy outcome, interval between first and second pregnancy 
bModel 2: Model 1 + socio-demographic variables (age, insurance status, race, education, adequacy of prenatal care received, WIC status) 




Table 5.4- Multivariate logistic regression analysis of subsequent pregnancy outcomes after maternal hep titis B viral infection. 
 Model 1a  Model 2b   Model 3c 
 OR (95% CI) P-value  OR (95% CI) P-value  OR (95% CI) P-value 
SGA (n=93,787)         
    Non disease- non disease (n=93,557) 1.00  1.00  1.00 
    Newly diagnosed (n=63) 2.05 (1.08-3.93) 0.03  1.85 (0.95-3.6) 0.06  1.85 (0.95-3.60) 0.07 
    Chronic carriers (n=167) 1.03 (0.66-1.73) 0.89  0.94  (0.55-1.58) 0.82  0.92 (0.54-1.55) 0.75 
AIC 57656  55318  54888 
Low birth weight (n=93,809)   
    Non disease- non disease (n=93,579) 1.00  1.00  1.00 
    Newly diagnosed (n=63) 1.28 (0.54-2.97) 0.56  1.11 (0.47-2.62) 0.81  1.07 (0.455-2.55) 0.87 
    Chronic carriers (n=167) 0.88 (0.4-1.64) 0.71  0.84 (0.43-1.56) 0.58  0.81 (0.40-1.49) 0.49 
AIC 47904  44990  44588 
Preterm (n=93, 814)   
    Non disease- non disease (n=93,584) 1.00   1.00  1.00 
    Newly diagnosed (n=63) 1.44 (0.70-2.94) 0.31  1.31 (0.63-2.71) 0.46  1.29 (0.62-2.68) 0.49 
    Chronic carriers (n=167) 0.82 (0.47-1.42) 0.49  0.84 (0.47-1.46) 0.52  0.81 (0.4-1.42) 0.47 
AIC 58821  55360  55053 
NICU Admission (n=93,814)   
    Non disease- non disease (n=93,584) 1.00  1.00  1.00 
    Newly diagnosed (n=63) 2.05 (0.87-4.78) 0.09  1.96 (0.83-4.60) 0.12  1.82 (0.77-4.30) 0.17 
    Chronic carriers (n=167) 1.43 (0.77-2.64) 0.25  1.48 (0.79-2.75) 0.21  1.488 (0.8-2.7) 0.21 
AIC 35014  34192  33957 
SGA= small for gestational age; NICU=neonatal intensive care unit; CI= confidence interval, AIC=Akaike information criterion. 
aModel 1: Adjusted for parity and previous adverse pr gnancy outcome and interval between first and second pregnancy) 
bModel 2: Model 1 + socio-demographic variables (age, insurance status, race, education, adequacy of prenatal care received, WIC status) 






























SUMMARY AND CONCLUSIONS 
Descriptive studies 
Both descriptive studies provided a characterization of the Hepatitis B and C virus (HBV, 
HCV) mono-infection and HBV/HIV, HCV/HIV and HBV-HCV co-infections among 
females in South Carolina. There was significant variation in the epidemiology of these 
infections in SC. In the HBV descriptive study, we estimated the prevalence of HBsAg 
among pregnant women to be 0.17% and found that HBV/ IV co-infection was 
substantial. Approximately 9% of chronic HBV cases in the study period were co-
infected with either HIV (4%) or HCV (5%).  Chronic HBV/HIV co-infected cases were 
more likely to be Black women from urban areas in SC, who reported heterosexual 
contact as the main risk factor for HIV transmission. These HBV co-infected cases also 
had low first CD4 counts after HIV diagnosis and there was a 9-year median time 
between HIV diagnosis and a subsequent HBV diagnosis. Taken together, these findings 
suggest that there are gaps in compliance with the recommended routine HBV screening 
and immunization for HIV-infected persons. Additionally, the findings indicate a missed 
opportunity for those with undiagnosed HBV to be put on appropriate medication that 
would treat both HIV and HBV.  Women between the ags of 20 and 49 reported the 




HBV infections reported from the Northeastern region (Pee Dee) of the state. We also 
found moderate agreement between CHESS and the birt registry data when we 
compared the degree of concordance for HbsAg positive cases reported during 
pregnancy. From these results we determined that disease surveillance of infections 
diagnosed during prenatal screening needed improvement. Additionally, our findings are 
suggestive to increase efforts to improve screening, reporting and prevention, especially 
among black women. 
In the HCV descriptive study we focused on describing the disease burden and 
characteristics associated with HCV, HCV/HIV and HCV-HBV co-infection. Results 
from this study revealed an emerging epidemic of HCV infections among young white 
females between the ages of 15 and 25 years in recet years. However, a large burden of 
HCV mono infection was still found in middle-aged white women. Four percent of cases 
were co-infected with HCV/HIV and they were more like y to black, whereas 1% of 
HCV cases were co-infected with HCV-HBV and they were more likely to be White. 
These findings suggest a need for resources to be directed at improving screening and 
prevention efforts among Black and White middle aged women and most especially, in 
young persons between the ages of 15 and 25 years. Also because HCV risk behavior and 
detailed race information were unavailable for analysis in our HCV surveillance data, 
initiatives to fund and improve HCV case reporting data are warranted. 
Spatial analysis of HCV infections 
An investigation into the spatial epidemiology of HCV infections in SC showed 
considerable differences in how HCV is distributed across the state. Our Bayesian spatial 




namely Charleston, Darlington, Florence, Georgetown, Greenville, Horry, Oconee, 
McCormick and Richland, represent a mixture of metropolitan and federally designated 
rural areas. McCormick county exhibited the highest risk for HCV infection even after 
the standardized morbidity ratio (SMR) had been spatially smoothed. This county also 
had the largest percentage of people of all ages living n poverty and the lowest 
percentage of persons, 24 or older, with at least a college degree. Our report of high HCV 
risks seen in rural SC corresponds to other recent reports of an emerging HCV epidemic 
in rural communities within the US which has been largely attributed to the increasing 
number of injecting drug users (IDU) in these areas.   
Even though we assessed drug treatment admissions data as potential explanatory 
covariate for HCV infection in the spatial model, it did not explain the observed spatial 
variation. This implies that other unobserved factors hat might account for the high HCV 
prevalence observed in these areas exists and will require further investigation. The 
infection prevalence map based on our spatial analysis provides a visual representation of 
how HCV disease is geographically dispersed. Information from the high-risk areas 
identified can used for policy decision-making and taking public health action. In 
addition, information from spatial and descriptive analysis can use to allocate resources 
more efficiently to help prevent and reduce the spread on HCV disease within the state.  
Birth outcomes study 
Even though the estimated national prevalence of HCV and HBV infections in the 
antenatal population may seem small, these prevalence correspond to several thousands 
of infected women who deliver babies annually and therefore constitute a public health 




is independently associated with HCV infection during pregnancy. Specifically, HCV-
infected women who transitioned from a non-diseased status to a diseased status in their 
subsequent pregnancy had significant higher odds of elivering babies that had a low 
birth weight. We found no significant associations between HCV infection, SGA, preterm 
birth and NICU admission. Also, no effect was detected for ‘chronic carrier’ women who 
were positive for HCV infection in their initial and subsequent pregnancies. We also 
found that being HBV-infected, be it a ‘recently diagnosed’ or ‘chronic carrier’ case, did 
not confer an additional risk for LBW, SGA, preterm birth and NICU admission.   
LBW is an important risk factor for infant mortality and from a practice point of 
view this information is useful for providers to advise infected expectant mothers on the 
potential risk to their baby. Additional population-based studies with more power are 
needed to determine if ‘chronic carriers’ of viral hepatitis poses a higher risk and future 
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SUMMARY OF LITERATURE REVIEW FINDINGS 
Table A.1 Summary of literature review findings by epidemiologic study design and 
location 
Author, year published 
and location Study design Statistical Analysis 
Sample size 
(Disease prevalence)  




T-test and Mann Whitney 




Elefsiniotis et al.,47 (2010) 
Greece Retrospective cohort Logistic regression 
70a 
 (3.8%)  




regression 450a  
Lao et al.,153 (2007) 
China Case-control Logistic regression 
1138a  
(8.3%)  
Tse et al.,45 (2005) 
China 
 
Case-control Logistic regression 253a  
To et al.,154 (2003) 
Hong Kong Case-control Not reported 
1340a 
(9.7%)  
Wong et al.,134 (1999) 
Hong Kong Case-control 




Haider et al.,56 (2009); 
Pakistan Case-control 2 tailed t-test 
23b 
(8.0%)  








Jaffery et al.,57 (2005) 
Pakistan Case-control Logistic regression 
31b 
(3.27%)  
Jabeen et al.,51 (2000) 
Ireland Case-control Not reported 26 c 
Hillemanns et al.,52 (2000) 
Germany Case-control 







Table A.1 Summary of literature review findings by epidemiologic study design and 
location (cont’d.) 
Author, year published 
and location Study design Statistical Analysis 
Sample size 
(Disease prevalence)  
Connell et al.,44 (2011) 
USA 
PB retrospective 
cohort Logistic regression 
1458e, 999f , 
(0.09%) (0.06%) 
Reddick et al.,48 (2011) 
USA Case-control Logistic regression 
814e, 555f, 
 
Safir et al.,49 (2010) 
Israel 
PB retrospective 
cohort Logistic regression 
749g 
(0.4%) 
Abbreviations: US=United States, MV=multivariable; PB=Population-based; MH= Mantel-Haensel; 
PCR=polymerase chain reaction; a HBsAg assessed with Elisa assay; b Elisa and PCR confirmed anti-HCV 
test ; c HCV RNA positive; d RIBA confirmed anti-HCV test eClinically diagnosed HBV from ICD-9-CM 
codes; fClinically diagnosed HCV from ICD-9-CM codes; g Anti-HCV or HBsAg positive cases 
 
Table A.2 Summary of literature review findings by study outcomes 
   
 Hepatitis B virus Hepatitis C Virus 
Maternal outcomes   N  N 
Gestational diabetes    (5)  (3) 
Premature rapture of membranes  (3)  (2) 
Preterm premature rapture of membranes  (1)   
Pre-eclampsia  (5)  (2) 
Intrauterine growth restriction  (1)  (2) 
Cesarean delivery    (2)  (5) 
Perinatal outcomes     
Preterm birth  (5)  (3) 
Small for gestational age  (3)  (2) 
Low birth weight  (2)  (5) 
Neonatal jaundice  (2)   
Apgar score (1 min)  (3)  (2) 
Assisted ventilation  (1)  (1) 
Spontaneous abortion    (1) 
Congenital abnormalities  (3)  (2) 
NICU admission  (2)  (1) 
Still birth  (1)   





CHARACTERISTICS OF SINGLETON PREGNANCIES INFECTED WITH HEPATITIS B OR C VIRUS, 
SOUTH CAROLINA , 2004-2011 
Table B.1 Characteristics of singleton pregnancies infected with Hepatitis B or C virus 

















(n = 266)  
Age in years, median (range) 28 (15 - 44) 26 (15 - 42) 28 (15 - 46) 27 (16 - 43) 26 (15 - 49) <0.0001c
< 20 years 37 (  6) 31 (11) 51 (  8) 14 (  5) 57388 (13) <0.0001
20-29 years 343 (55) 159 (56) 339 (52) 150 (56) 250132 (57) 
≥ 30 years 243 (39) 93 (33) 257 (40) 102 (38) 128869 (30) 
Race/ethnicity      
Non-Hispanic White 479 (77) 164 (58) 122 (19) 79 (30) 240905 (55) <0.0001
Non-Hispanic Black 105 (17) 82 (29) 286 (44) 112 (42) 143767 (33) 
Hispanic 22 (  4) 21 (  7) 36 (  6) 27 (10) 41164 (  9) 
Other 16 (  3) 15 (  5) 197 (30) 46 (17) 9121 (  2) 
Maternal education      
< High school  204 (33) 71 (25) 192 (30) 68 (26) 100545 (23) <0.0001
High school 206 (33) 81 (29) 186 (29) 76 (29) 112169 (26) 
Beyond high school 211 (34) 128 (45) 263 (41) 121 (45) 222319 (51) 
Did mother use WIC      
Yes 434 (70) 151 (53) 371 (57) 143 (54) 234108 (54) <0.0001
No 173 (28) 123 (43) 265 (41) 111 (42) 194816 (45) 
Unknown 16 (  3) 9 (  3) 11 (  2) 12 (  5) 7465 (  2) 
Payment source for delivery      
Medicaid 473 (76) 148 (52) 352 (54) 149 (56) 216579 (50) <0.0001
Private Insurance 95 (15) 97 (34) 200 (31) 58 (22) 162793 (37) 
Self-pay 29 (  5) 18 (  6) 61 (  9) 27 (10) 28608 (  7) 
Other 25 (  4) 15 (  5) 29 (  4) 27 (10) 23881 (  5) 
Did mother smoke during 
pregnancy 
     
Yes 342 (55) 74 (26) 58 (  9) 46 (17) 56283 (13) <0.0001
No 281 (45) 209 (74) 588 (91) 219 (82) 379845 (87) 
STI present during 
pregnancyd? 
     
Yes 69 (11) 19 (  7) 75 (12) 31 (12) 30546 (  7) <0.0001




Table B.1 Characteristics of singleton pregnancies infected with Hepatitis B or C virus 
compared to non-infected pregnancies, South Carolin, 2004-2011 (cont’d.) 
 














(n = 266) 
 
(n = 436,389) 
Parity       
Nulliparous 158 (25) 120 (42) 207 (32) 82 (31) 182088 (42) <0.0001 
Multiparous 465 (75) 163 (58) 439 (68) 184 (69) 254201 (58)  
History of alcohol abusee       
Yes 108 (17) 12 (  4) 21 (  3) 13 (  5) 7123 (  2) <0.0001 
No 515 (83) 271 (96) 626 (97) 253 (95) 429266 (98) 
History of drug usee      
No 394 (63) 266 (94) 631 (98) 254 (95) 427210 (98) <0.0001
Yes 229 (37) 17 (  6) 16 (  2) 12 (  5) 9179 (  2) 
Primary route of drug use      
Injection 
/intramuscular 
79 (34) 4 (24) 0 1 (  8) 482 (  5) <0.0001f
Other 150 (68) 27 (76) 16 (100) 11 ( 92) 8697 (95) 
BMI pre-pregnancy, 
kg/m2 
     
Underweight 36 (  6) 10 (  4) 37 (  6) 15 (  6) 18526 (  4) 0.234
Normal weight 272 (44) 123 (43) 275 (43) 105 (39) 180693 (41) 
Overweight 158 (25) 73 (26) 145 (22) 63 (24) 107923 (25) 
Obese  143 (23) 74 (26) 180 (28) 79 (30) 120239 (28) 
Gestational weight gaing       
Adequate 126 (20) 58 (20) 160 (25) 64 (24) 100113 (23) <0.0001
Inadequate 209 (34) 78 (28) 195 (30) 80 (30) 108535 (25) 
Excessive 197 (32) 100 (35) 203 (31) 88 (33) 160718 (37) 
Missing 91 (15) 47 (17) 89 (14) 34 (13) 67023 (15) 
Previous adverse 
outcomeh 
     
No 533 (86) 253 (89) 567 (88) 235 (88) 398887 (91) <0.0001
Yes 90 (14) 30 (11) 80 (12) 31 (12) 37502 (  9) 
Risk factors present in 
pregnancy 
     
No 408 (65) 214 (76) 452 (70) 194 (73) 329348 (75) <0.0001
Yes 215 (35) 69 (24) 195 (30) 72 (27) 107041 (25) 
APCU indexi      
Inadequate 224 (36) 74 (26) 162 (25) 85 (32) 87457 (20) <0.0001
Intermediate 51 (  8) 20 (  7) 49 (  8) 19 (  7) 31960 (  7) 
Adequate 118 (19) 80 (28) 178 (28) 54 (20) 124432 (29) 
Adequate plus 226 (36) 106 (37) 250 (39) 104 (39) 188974 (43) 
Unknown 4 (<1) 3 (  1) 8 (  1) 4 (  2) 3566 (<1) 
CHESS=South Carolina Health Electronic Surveillance System; BC = birth certificate (registry) data; HBV= hepatitis B 




Characteristics of singleton pregnancies infected with Hepatitis B or C virus, South 
Carolina, 2004-2011 (cont’d) 
WIC=women, infant and children nutrition program, APCU= adequacy of prenatal care utilization. 
a These include 37 pregnancies confirmed in CHESS as acute HBV cases. 
b Pearson Chi-square test 
cKruskall Wallis test  
dSTI infections include presence of either chlamydia, gonorrhea, syphilis or genital herpes infection fr that pregnancy 
eData from Department of drug, alcohol and other drugs. Indicates if patient has received treatment servic s for drug or 
alcohol addiction 
fFisher exact test 
gAccording to the Institute of Medicine guidelines 







SAS OUTPUT FREQUENCIES FOR PREGNANCY OUTCOMES BY HEPATITIS B OR C INFECTION 
STATUS AT THE TIME OF A SUBSEQUENT PREGNANCY 
 
 
SAS output frequencies 
Hepatitis C   Cases Hepatitis B   Cases
Small for gestational age Small for gestational age
newgroup_hcv No Yes Total newgroup_hcv No Yes Total
No disease 84947 8610 93557 No disease 84947 8610 93557
Newly diagnosed 103 21 124 Newly diagnosed 52 11 63
Chronic carriers 129 19 148 Chronic carriers 151 16 167
Total 85179 8650 93829 Total 85150 8637 93787
newgroup_hcv No Yes Total newgroup_hcv No Yes Total
No disease 86871 6708 93579 No disease 86871 6708 93579
Newly diagnosed 102 22 124 Newly diagnosed 57 6 63
Chronic carriers 135 13 148 Chronic carriers 156 11 167
Total 87108 6743 93851 Total 87084 6725 93809
newgroup_hcv No Yes Total newgroup_hbv No Yes Total
No disease 84533 9051 93584 No disease 84533 9051 93584
Newly diagnosed 104 20 124 Newly diagnosed 54 9 63
Chronic carriers 132 16 148 Chronic carriers 153 14 167
Total 84769 9087 93856 Total 84740 9074 93814
newgroup_hcv No Yes Total newgroup_hbv No Yes Total
No disease 89214 4370 93584 No disease 89214 4370 93584
Newly diagnosed 114 10 124 Newly diagnosed 57 6 63
Chronic carriers 139 9 148 Chronic carriers 156 11 167










ASSESSMENT OF SELECTION BIAS 
Table D.1 Comparison of maternal characteristics betwe n all prospectively observed women 
with singleton pregnancies, all women with subsequent pregnancies and study sample at the time 








Study sample at 
time of subsequent 
pregnancy 
(N= 95,291)  
Age at delivery in years, 
median (range) 26 (15 - 49) 25 (15 - 49) 26 (15 - 49) 
<20 years 57521 (13) 28838 (14) 6581 ( 7) 
20-29 years 251113 (57) 130370 (62) 58766 (62) 
>=30 years 129544 (30) 52124 (25) 29944 (31) 
Race/Ethnicity  
Hispanic 41268 ( 9) 19133 ( 9) 8701 ( 9) 
Non-Hispanic White 241736 (55) 114466 (54) 52553 (55) 
Non-Hispanic Black 144342 (33) 73603 (35) 32236 (34) 
Other 9391 ( 2) 3494 ( 2) 1605 ( 2) 
Education  
< High school 101069 (23) 56384 (27) 22081 (23) 
High school 112708 (26) 55287 (26) 25133 (26) 
Beyond High school 223033 (51) 98964 (47) 47755 (50)
WIC usage  
No 195476 (45) 92998 (44) 44718 (47) 
Yes 235190 (54) 114660 (54) 48921 (51) 
Payment source for delivery  
Medicaid 217681 (50) 113223 (54) 49832 (52) 
Private Insurance 163240 (37) 73949 (35) 35433 (37) 
Self-pay 28739 ( 7) 14007 ( 7) 5973 ( 6) 
Other 23974 ( 5) 7980 ( 4) 3404 ( 4) 
Smoking  
No 381120 (87) 182752 (86) 82639 (87) 
Yes 56795 (13) 28452 (13) 12585 (13) 
Any STI present?  
No 407439 (93) 195637 (93) 88555 (93) 




Table D.1 Comparison of maternal characteristics betwe n all prospectively observed 
pregnancies, women with subsequent pregnancies and tudy sample at time of subsequent 
pregnancy, South Carolina, 2004-2011 (cont’d.) 
*Percentages may not equal to 100 because of rounding. 

















Pre-pregnancy BMI     
Underweight, BMI<18.5 18623 ( 4) 9232 ( 4) 3620 ( 4)
Normal weight, 18.5<=BMI<25 181460 (41) 87672 (41) 37148 (39) 
Overweight, 25<=BMI<30 108349 (25) 52034 (25) 24063 (25) 
Obese, BMI>=30 120707 (28) 57965 (27) 28350 (30) 
Previous adverse pregnancy outcome  
No 400449 (91) 192036 (91) 85186 (89) 
Yes 37729 ( 9) 19296 ( 9) 10105 (11) 
Risk factors present in pregnancy  
No 330594 (75) 158170 (75) 64925 (68) 
Yes 107584 (25) 53162 (25) 30366 (32) 
History of alcohol use  
No 430905 (98) 207415 (98) 93586 (98) 
Yes 7273 ( 2) 3917 ( 2) 1705 ( 2) 
History of drug use  
No 428730 (98) 205557 (97) 92804 (97) 
Yes 9448 ( 2) 5775 ( 3) 2487 ( 3) 
Adequacy of prenatal care  
Missing 3584 (<1) 1648 (<1) 549 (<1) 
Inadequate 87996 (20) 45407 (21) 20468 (21) 
Intermediate 32098 ( 7) 15601 ( 7) 6679 ( 7) 
Adequate 124854 (28) 60105 (28) 27955 (29) 
Adequate plus 189646 (43) 88571 (42) 39640 (42) 
